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Clinical features of Huntington’s disease (HD) include motor, neuropsychiatric and cognitive 
symptoms[1]. HD is an autosomal dominant inheritable neurodegenerative disorder. This im-
plies that, if one of the parents is afflicted, their offspring has a 50% probability of developing HD. 
Although neuropsychiatric and cognitive symptoms often precede the manifestation of motor 
abnormalities of HD, the definite diagnosis of HD is usually made when the first motor symp-
toms occur. Although the age of onset is wide (ranging from early childhood to senescence), it is 
generally between 30 and 50 years of age. The duration between the time of diagnosis and death is 
around 20 years[2]. Motor symptoms may initially be subtle and might, at first, escape the aware-
ness of the patient. Chorea is the most prominent motor symptom in HD and is characterized by 
involuntary irregular movements of the head, trunk and limbs. Other movement disorders, such 
as dystonia, bradykinesia, hypokinesia and postural instability, also occur[3]. In advanced stages 
of the disease, dysphagia and dysarthria may also develop[4].
neuropsyChIatrIC symptoms In hd
In HD, the most prevalent neuropsychiatric symptoms are depressed mood, irritability and 
apathy. The prevalence of depressed mood ranges from 33-69%. Apathy and irritability occur fre-
quently in HD with a reported prevalence of 34-76% for apathy and of 33-73% for irritability[1]. 
Apathy is defined as a disorder of motivation with diminished goal-directed behavior, 
cognitions and emotions[5]. Apathy is positively correlated with cognitive decline, male sex, 
the presence of depression, and the use of psychotropic medication[6]. Longitudinally, although 
new-onset apathy was shown to occur in 14% of HD gene expansion carriers over a two-year 
study period, apathy also remitted in 14% during that same time period[7], indicating the poten-
tial for remittance. This suggests that HD patients with apathy should be evaluated for treatable 
causes of apathy. 
Irritability can be characterized as a dysphoric mood state that predisposes toward both 
verbal and non-verbal expressions of aggression in a non-adaptive manner that complicates 
the relationship between the patient and the caregiver and/or partner[8]. Even before motor 
symptoms are present, irritability can cause severe distress to HD patients and their caregivers. 
In pre-motor symptomatic disease stages, cognitive dysfunction mostly comprises deficits 
in attentional and executive functions, semantic verbal fluency and visual working memory. 
Deficits in memory become apparent around the time of onset of motor symptomatic disease. In 





The causal genetic mutation was discovered in 1993 and comprises an expanded cytosine-
adenine-guanine (CAG) trinucleotide repeat coding for the huntingtin (htt) protein on the short 
arm of chromosome 4 (4p16.3)[10]. Persons with an expansion of >39 CAG repeats will develop 
the disease, although an expansion of 36-39 CAG repeats may also result in symptomatic HD 
(‘reduced penetrance’). The expanded gene codes for mutant huntingtin (mhtt)[11]. A greater 
CAG repeat length is associated with an earlier age of onset of symptoms. 
Neurodegeneration is a prominent feature of HD. In HD, there is neuronal cell loss in the 
brain, particularly in the caudate nucleus and the putamen, but also in other brain regions, 
including the cortex. This loss of neurons is already detectable in pre-motor symptomatic HD 
gene expansion carriers[12]. In physiological circumstances htt is expressed in all cells (with the 
highest concentrations in the brain and testes) and plays a key role in transcription, cell signaling 
and intracellular transporting[13]. However, much remains unknown about the physiological 
function of htt as well as the exact pathophysiology by which mhtt causes cerebral tissue damage. 
Several mechanisms are likely to play a role in the neurodegenerative process, including increased 
excitotoxicity, mitochondrial damage, free radical formation, and immune activation[14]. 
Immune system and InflammatIon In hd
Aberrant immune activation is one of the proposed underlying mechanisms for neurodegenera-
tion and, subsequently, the development of the characteristic symptoms in HD[14]. Microglia, 
the main immunocompetent cells in the central nervous system, play a key role in immune pro-
cesses in the brain[15]. Activated microglia have been demonstrated in post-mortem samples of 
patients with HD and on cerebral positron emission tomography (PET) scans[16, 17]. Mhtt may 
play an important role in the activation of microglia by directly activating the nuclear transcrip-
tion factor-kB (NF-kB), thereby initiating the first steps of the acute-phase response [18]. Also, 
mhtt can activate the IkB kinase complex, thereby enhancing activity of the nuclear transcription 
factor NF-kB[18]. NF-kB plays a key role in the regulation of the immune response to infec-
tion[19]. Alternatively, cell damage caused by mhtt through other mechanisms may activate the 
acute-phase response. The NF-kB pathway is a major inducer of the pro-inflammatory cytokines 
interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α. Among these cytokines, IL-6 is the 
most potent inductor of the acute-phase response[20], a systemic reaction aimed at restoring 
physiological homeostasis under physiologic circumstances[21]. This response is regulated by 
several other pro-inflammatory and anti-inflammatory cytokines such as IL-8 and IL1-ra, IL-5 
and IL-10, respectively. As part of this systemic reaction, the production of certain proteins is 
upregulated or downregulated to the benefit of the injured organism[22, 23]. As such, the pro-
duction of C-reactive protein (CRP), that plays a prominent role in the complement cascade, is 
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upregulated and its circulating level can be thought of as a positive acute-phase protein, whereas 
the production of albumin is downregulated and its circulating level can therefore be thought of 
as a negative acute-phase protein. 
BIomarkers of dIsease state In hd
Biomarkers are important because they may provide an early indication as to whether (or 
not) a potential therapeutic intervention is beneficial. A useful biomarker needs to be readily 
quantifiable, robust and reproducible [12, 24, 25]. In HD, biomarkers of several modalities have 
been employed to observe differences between HD gene expansion carriers and controls, and to 
observe differences between HD gene expansion carriers at different disease stages, or even to 
observe differences in HD gene expansion carriers before disease onset[12]. 
Clinical measures are regularly used as markers of disease stage in HD investigations. One 
of the most frequently used clinical rating scales is the Unified Huntington’s Disease Rating Scale 
(UHDRS) which comprises subscales on several domains, such as daily functioning and mo-
tor symptoms. In general, the UHDRS scale measures changes in symptomatic HD over time, 
but is not able to detect changes in pre-motor symptomatic HD. In addition, neuropsychiatric 
measures, such as the Problem Behaviours Assessment (PBA) scale, are used to assess specific 
neuropsychiatric features of the disease. 
Structural magnetic resonance imaging (MRI) is widely used to define cerebral biomarkers 
in HD gene expansion carriers. Cross-sectionally, MRI can show disease-related atrophy of the 
striatum and white matter of HD gene expansion carriers compared with controls. This atrophy 
can be demonstrated years before the onset of clinical disease. In addition, using MRI, progres-
sive neurodegenerative changes can be demonstrated in early HD and pre-motor symptomatic 
HD gene expansion carriers. 
However, information from biochemical biomarkers might be obtained more rapidly (and 
at less cost) compared with imaging markers. In addition, biochemical markers that are in close 
proximity to the underlying pathology may be more sensitive to disease progression and might 
show reversal in response to therapeutic interventions. Cytokine levels in the plasma are poten-
tial biochemical biomarkers in HD. Increased levels of several cytokines have been reported in 
cross-sectional studies among HD gene expansion carriers[26-30]. Most consistently, plasma 
IL-6 levels were higher in motor symptomatic HD gene expansion carriers than in matched 
controls. Also, increased plasma levels of sIL-2R, sTNF-α and IL-8 were found compared with 
levels in controls. 
Cytokines and acute-phase proteins in relation to neuropsychiatric symptoms in HD
The acute-phase response involves a systemic reaction of the immune system as reflected in 
activation of monocytes, which is regulated by several cytokines[20, 21]. In addition, metabolic 
Chapter 1
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changes occur, such as the production of certain acute-phase proteins and the inhibition of pro-
duction of other molecules [22, 23]. These changes, which are readily quantifiable in the blood, 
may be accompanied by behavioral changes that favor the survival of the organism when the ho-
meostasis is disturbed. In mouse models, behavioral changes (such as psychomotor retardation, 
anorexia, sleep disturbances and lethargy) have been called ‘sickness behavior’. Changed levels of 
cytokines in the brain may also cause part of these behavioral effects in humans[31]. Reciprocal 
connections exist between the peripheral immune system and the brain[31-34]. Cytokines in the 
peripheral plasma can pass the blood-brain barrier under certain conditions and can activate 
nerve cells that stimulate immune cells in the brain to produce cytokines. 
Given this bidirectional association between plasma and brain cytokines and behavior, sev-
eral studies have examined the connection between cytokines and neuropsychiatric symptoms 
in non-HD populations. The association between cytokines, acute-phase proteins and depression 
has been investigated the most extensively[35-37]. Consistently increased levels of IL-6 and CRP 
were found in (non-HD) depressed patients. In addition, the association between cytokines 
and cognitive decline, as well as dementia, yielded similar results[38]. The association between 
cytokines and irritability and apathy has also been investigated in non-HD populations, but with 
inconsistent results[37, 39-44].
In HD, neuropsychiatric symptoms (in particular psychosis and irritability) and motor 
symptoms are frequently treated with antipsychotic medications[45]. However, antipsychot-
ics can induce symptoms that can mimic apathy, depressive mood and cognitive decline[46]. 
Through several (hepatic) mechanisms, antipsychotics may adversely influence plasma levels of 
cytokines and acute-phase proteins[47-49]. In addition, metabolic disturbances are a well-known 
side-effect of antipsychotics, which is associated with low-grade inflammation[50]. Therefore, 
the use of antipsychotics is a potential confounder of the relationship between cytokine levels 
and acute-phase proteins on the one hand and neuropsychiatric symptoms on the other, and 
should be taken into account when investigating these relationships. 
aIms and outlIne of thIs thesIs
The aim of this thesis was to get a better understanding of the incidence and course of neuro-
psychiatric symptoms in HD, particularly irritability that is a core behavioral symptom. Also, 
we aimed to investigate the relationship between activity of the immune system and presence of 
neuropsychiatric symptoms. We expected to find a relation between neuropsychiatric symptoms 
and increased pro-inflammatory activity of the immune system, and, given the findings of ear-
lier studies, we expected this activity to further increase in more advanced disease stages. This 
aberrant immune state drives neuroinflammation and in turn causes neuronal dysfunction and 
in the end, cell-death. We hypothesized that these pathological changes would be reflected in 
occurrence of neuropsychiatric symptoms. Therefore, we expected to find that neuropsychiatric 
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symptoms would increase as activity of the immune system increased as measured by levels 
of cytokines in the plasma. In Chapter 2, the psychometric properties of the Irritability Scale 
were assessed in order to reliably measure and detect irritability in HD. Also, because environ-
mental factors play an important role in HD psychopathology, in Chapter 2 and Chapter 3, 
we investigated sociodemographic and clinical characteristics that correlated with irritability, or 
could predict irritability. The role of some parts of the innate immune system was investigated 
using both plasma acute-phase proteins and cytokines in relation to neuropsychiatric symptoms 
and cognitive dysfunction in HD. In Chapter 4, the relation between acute-phase proteins and 
neuropsychiatric symptoms, and the use of psychotropic medication in HD, were examined. 
The studies in Chapter 5 investigated the role and usefulness of immune system parameters 
as biomarkers in HD. In a longitudinal study design, we aimed to investigate whether cytokine 
levels correlated with disease stage and whether cytokine levels changed in conjunction with 
changes in disease stage. In Chapter 6, plasma cytokine levels were investigated in relation to 
neuropsychiatric symptoms and cognitive dysfunction in HD. Finally, in Chapter 7, our findings 
are summarized and considered within the current perspective, methodological and clinical 
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Irritability in huntington’s disease
W. Reedeker, J.A. Bouwens, E.J. Giltay, S.E. Le Mair, 
R.A.C. Roos, R.C. van der Mast, E. van Duijn




Irritability is a frequent neuropsychiatric symptom in patients with Huntington’s disease (HD). 
The Irritability Scale (IS) and the irritability factor of the Problem Behaviours Assessment (PBA) 
was used to assess irritability among 130 HD mutation carriers and 43 verified non-carriers. The 
IS was tested using receiver operating characteristic analysis against different cut-offs of the PBA 
irritability factor. A robust IS cut-off score of ≥14 points was found indicating that 45 (35%) of 
the 130 mutation carriers were irritable vs. 4 (9%) of the 43 non-carriers (P=0.001). The level 
of agreement between self-report and informant-report IS was of moderate strength (intraclass 
correlation=0.61). Using univariate and multivariate regression analyses, independent correlates 
of irritability were: being married/living together (P=0.02), CAG repeat length (P=0.01), and 
use of benzodiazepines (P=0.008). Using the same model with the informant’s irritability score, 
use of benzodiazepines was the only significant independent correlate of irritability (P=0.005). 
Irritability is a prominent symptom of HD and can be reliably assessed with the IS using a cut-
off score ≥14 points. Although it is unclear whether benzodiazepine use causes irritability, or 
irritability leads to the prescription of benzodiazepines, clinical evaluation with respect to the 
use of benzodiazepines in HD warrants attention.
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Irritability in Huntington’s disease
IntroduCtIon
Huntington’s disease (HD) is a progressive autosomal dominant neurodegenerative disorder 
resulting from an expanded trinucleotide cytosine-adenine-guanine (CAG) repeat in the hun-
tingtin (HTT) gene on chromosome 4 (Huntington’s Disease Collaborative Research Group, 
1993). Clinical features of HD include motor disturbances, cognitive deterioration and a variety 
of psychiatric symptoms (Walker, 2007). Psychiatric symptoms such as depressed mood, perse-
verative behaviour, and irritability are frequently reported, and often precede the manifestation 
of motor abnormalities of HD (Paulsen, 2001; Duff, 2007; van Duijn, 2007).
Despite its frequent occurrence, negative clinical consequences for mutation carriers and its 
heavy burden for caregivers, irritability has scarcely been studied in HD. The term ‘irritability’ 
has been used as a description of behavior ranging from bad temper to violent outbursts, but is 
also defined as a mood state characterized by a reduction in control over temper possibly but not 
necessarily resulting in verbal or behavioral outbursts (Snaith, 1985; Craig, 2008).
Few reliable data on the true prevalence of irritability in HD exist due to small sample sizes, 
use of different methodologies, and lack of control groups. Reported prevalence rates for ir-
ritability range from 38–73% (van Duijn, 2007). This variation in prevalence can be explained by 
the use of different assessment methods with varying definitions and different study populations. 
No follow-up studies have covered a long period of time. Irritability may occur in all stages of 
HD, even before motor symptoms are present, and may cause severe distress to mutation carriers 
and their families, determining the need for admittance to a nursing home.
The instruments used to assess the presence and severity of irritability in HD include the 
Neuropsychiatric Inventory (NPI) (Paulsen, 2001; Kulisevsky, 2001). The behavioural section of 
the Unified Huntington’s Disease Rating Scale (UHDRS-b) (Murgod, 2001), the Irritability Scale 
(IS) (Chatterjee 2005; Klöppel, 2010), and the Problem Behaviours Assessment (PBA) (Craufurd, 
2001; Kingma 2008). However, no gold standard (cut-off) for assessing the presence of irritability 
is available.
The present study uses the IS and the PBA to assess irritability in HD. The aim was to in-
vestigate the psychometric properties of the IS against the irritability factor of the PBA, in order 
to establish reliable cut-off scores for irritability with high sensitivity and specificity. Prevalence 




Between May 2004 and August 2006, HD mutation carriers and first-degree non-carriers were 
recruited from the outpatient department of Neurology and Clinical Genetics of the Leiden 
Chapter 2 
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University Medical Centre (LUMC) and from a regional nursing home. Subjects with a CAG 
repeat length of 36 or more repeats were considered to be HD mutation carriers. Details of the 
study design are described elsewhere (Kingma, 2008). A second measurement was conducted 
two years after the baseline visit.
Since the use of the IS was introduced while the first wave was already underway, subjects 
for this study comprised (non-overlapping) 130 mutation carriers and 43 non-carriers from both 
the first and second waves. Additional information was available from 120 informants of the 130 
mutation carriers and from 38 informants of the 43 non-carriers. Of the 120 mutation carriers’ 
informants, 70 were spouses or partners, 4 were neighbours or friends, 10 were first-degree fam-
ily members, 15 were specialized caregivers, and the status of 21 informants was unknown. The 




The IS was used to assess irritability (Figure 1); this scale has previously been used to assess 
irritability in HD (Chatterjee, 2005; Klöppel, 2010). The IS poses 14 questions about the presence 
of various phenomena of irritability in the two weeks prior to the interview. Each question has 
four answer categories scored on a 4-point Likert scale: ‘not at all’, ‘slightly’, ‘some’, and ‘a lot’. 
The total sum score of the IS ranges from 0 to 42 points, with higher scores indicating more 
severe irritability. The participant was asked to rate the self-report version of the IS (IS-self) 
and the informant was asked to rate the irritable behaviour of the participant with the identi-
cal informant-report version of the IS (IS-informant). Until now, no studies have assessed the 
psychometric properties of the IS.
The PBA is a reliable instrument to assess neuropsychiatric symptoms in HD (Craufurd, 
2001; Kingma, 2008). The severity and frequency of each of the 36 items of the PBA are rated on a 
scale from 0 to4 points, with higher scores indicating more psychopathology. The interrater reli-
ability of the PBA was 0.82 (95%CI=0.65–1.00) for severity scores and 0.73 (95%CI=0.47–1.00) 
for frequency scores (Kingma, 2008). A factor analysis of the PBA revealed three symptom clus-
ters (factors): irritability, depression, and apathy. The irritability factor of the PBA consists of five 
items: ‘irritability’, ‘aggression’, ‘verbal outbursts’, ‘inflexibility’, and ‘self-centeredness/demanding 
behaviour’ (Kingma, 2008). The irritability factor score is obtained by the sum of the multiplied 
frequency and severity scores of the five items (range 0–80 points). We chose to validate the 
IS against the PBA irritability factor, as we consider the PBA to be the best measurement tool 
available to assess irritability in HD.
Since the UHDRS-b is widely used in HD studies, we also scored the severity and frequency 
of the 11 neuropsychiatric items of this scale (Huntington Study Group, 1996). Severity and 
frequency are rated on a scale from 0 to 4 points, with higher scores indicating more psychopa-
thology.
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Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics of mutation carriers and controls 
was collected in a standardized manner. Global daily functioning was assessed with the Total 
Functional Capacity (TFC) scale of the UHDRS (Shoulson, 1979). The TFC consists of five ques-
tions assessing employment, capacity to handle financial affairs, capacity to manage domestic 
chores, capacity to perform activities of daily living, and the care level provided, with higher 
scores indicating better functional capabilities. The neurological examination was performed 
by a neurologist with experience in HD, blinded for the genetic status of the subject. Motor 
functioning was assessed according to the motor section of the UHDRS (UHDRS-m) (Hun-
Are you easily irritated?
Do you pout if things don't go your way? 
Do you have good control of your temper with the family 
(or persons living with you)? 
Do little things cause you to fly off the handle? 
Do you adjust well to a change in plans?
When you lose your temper, do you have a hard time 
calming down again? 
Do you insist on having your own way? 

















Can you discuss problems together and agree to a 
reasonable solution?
Do disagreements often lead to arguments? 
Can you appreciate a different point of view from yours? 
Do you yell a lot? 
Are you able to control your temper with persons outside 
the family? 
0 1 2 3
0 1 2 3
3 2 1 0
0 1 2 3
3 2 1 0
0 1 2 3
0 1 2 3
0 1 2 3
3 2 1 0
0 1 2 3
3 2 1 0
0 1 2 3
3 2 1 0
0 1 2 3Do you consider yourself to be irritable? 
















figure 1 Irritability Scale (self-report version) with the level of agreement between self-reported 
and informant-reported level of irritability.
* Level of agreement for each score between IS-self and IS-inf as determined by ICC with a 1-way random effects model with 
single-measure reliability. 
ICC = Intraclass Correlation Coefficients;
IS-self = Irritability Scale self-report;
IS-inf = Irritability Scale informant-report.
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tington Study Group, 1996). Mutation carriers with UHDRS Confidence Level score 0 or 1 were 
considered pre-motor symptomatic and mutation carriers with Confidence Level score >1 were 
considered motor symptomatic. Estimated duration of disease was calculated by the estimated 
age of onset according to the equation of Vassos et al.: ln [age of onset (years)] = 6.18 – 0.054 * 
[CAG repeats (number)] minus the current age(Vassos, 2008).
Assessment of cognitive functioning
The Mini-Mental Status Examination (MMSE) (Folstein, 1975), Symbol Digit Modalities Test 
(SDMT) (Smith, 1968), Verbal Fluency Test (VFT) (Hodges, 2009), and Stroop tests (Stroop, 
1935) were administered to assess both global and frontal executive cognitive functioning.
Assessment of psychiatric disorders
The Dutch translation of the computerised version of the Composite International Diagnostic 
Interview (CIDI, version 2.1) (Robins, 1989) was used to assess the presence of a depressive dis-
order according to the criteria of the Diagnostic and Statistical Manual of mental disorders, 4th 
edition (DSM-IV) (American Psychiatric Association, 2000). The CIDI was not administered in 
subjects with MMSE score <18 points, since the CIDI cannot be reliably administered to patients 
with severe cognitive dysfunction.
Statistical analyses
Data are presented as n (%), mean (± standard deviation (S.D.)), or median (inter-quartile range 
(IQR)) when appropriate. Chi-square tests for categorical data, t-tests for independent samples 
with normal distribution, or nonparametric Mann-Whitney U tests were conducted to compare 
mutation carriers and non-carriers. Convergent validity was assessed by Spearman’s correlation 
coefficient. Kruskal-Wallis tests were conducted to compare IS-self and IS-informant scores 
among the three groups of non-carriers, pre-motor symptomatic carriers, and motor symptom-
atic mutation carriers. Cronbach’s alpha was assessed as a measure for internal consistency of the 
IS-self and IS-informant.
Because no known cut-off score exists for the presence of irritability as assessed with the IS, 
Receiver Operator Characteristic (ROC) analyses were performed against different cut-offs (i.e. 
10, 15, and 20 points) of the irritability factor of the PBA that yielded optimal sensitivity and 
specificity. The area under the ROC curve (AUC) was used as an indicator of the discriminatory 
power of the IS to distinguish between irritable and non-irritable subjects according to the ir-
ritability factor of the PBA.
Using univariate logistic regression analyses, mutation carriers with IS score ≥14 points 
were compared to those with IS score <14 points to determine correlates of irritability. Odds 
ratios (OR) and their corresponding 95% confidence interval (CI) were computed. Because of a 
non-normal distribution of TFC, UHDRS-m and MMSE scores, these data were dichotomized 
using a median split. To yield the independent correlates of irritability (IS-self), multiple lo-
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gistic regression analysis with a forward selection procedure was used, selecting the following 
univariate correlates with P<0.10: being married/living together with a partner, CAG repeat 
length, TFC, use of benzodiazepines, and Stroop interference test. This model was adjusted for 
age and sex (i.e., forced into the model). In addition, the same variables were entered using the 
IS-informant score as the dependent variable. In sensitivity analyses, models were repeated using 
different cut-off scores of the IS.
Agreement between IS-self and IS-informant scores was assessed using one-way random, 
single measure intraclass correlation coefficients (ICCs). The same analysis was performed to 
assess the level of agreement on each of the 14 items of the IS. All tests were two-tailed with 
P<0.05 denoting statistical significance. The SPSS version 16.0 (SPSS Inc., Chicago, USA) was 
used for the analyses.
results
Sociodemographic, clinical, and neuropsychiatric characteristics
Table 1 presents the sociodemographic, clinical and neuropsychiatric characteristics of the 
130 (39 pre-motor symptomatic and 91 motor symptomatic) HD mutation carriers and the 43 
non-carriers. Mutation carriers were older and less often married/living together with a partner 
than non-carriers. Mutation carriers had significantly higher irritability scores (both IS-self and 
IS-informant) than non-carriers, and 45 (35%) of the 130 mutation carriers were irritable ac-
cording to an IS-self score ≥14 points, compared to 4 (9%) of the 43 non-carriers. Although the 
CIDI assessment was not possible in 11 mutation carriers due to severe cognitive impairment 
(MMSE<18 points), there were 13 (10%) mutation carriers, of whom 8 had a major depressive 
disorder vs. one (2%) non-carrier with a psychiatric disorder.
Psychometric properties of the Irritability Scale
Cronbach’s alphas were 0.90 for the IS-self and 0.93 for the IS-informant. There was some evi-
dence for convergent validity with the irritability item of the UHDRS-b indicated by Spearman’s 
correlation coefficient of 0.56 (P=0.001, n=32 with complete data for both scales). Using ROC 
analysis, a score of ≥14 points on the IS-self was identified as a robust indicator for irritability 
according to all three different cut-off points (10, 15, and 20 points) of the irritability factor 
of the PBA; the three cut-off points corresponded to prevalence rates of 33%, 22% and 12% of 
irritability (Table 2; Figure 2). The IS cut-off score of ≥14 points yielded an acceptable sensitivity 
and high specificity for all three cut-off points.
Level of agreement between the IS-self and IS-informant scores
The overall ICC for IS-self and IS-informant scores was 0.61 (95%CI=0.50–0.72, P<0.001) (Figure 
3A). The ICC for IS-self and IS-informant was higher (ICC=0.75) when spouses/partners were 
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table 1. Sociodemographic and clinical characteristics of HD mutation carriers and non-carriers.
mutation carriers non-carriers p-value*
(n = 130) (n = 43)
sociodemographic and clinical characteristics
Male (n, %) 58 (45) 20 (47) 0.83
Age, years (mean ± SD) 49 ± 11 41 ± 11 < 0.001
Higher level of education a (n, %) 78 (60) 31 (72) 0.17
Married/living together (n, %) 81 (62) 35 (81) 0.02
Excessive use of alcohol (n,%) 13 (10) 1 (2) 0.14
CAG repeat length (mean ± SD) 44 ± 3 22 ± 4 < 0.001
neuropsychiatric characteristics
IS-self (median, IQR) 9 (3 – 17) 5 (2 – 9) 0.01
IS-self with cut-off ≥ 14 (n, %) 45 (35) 4 (9) 0.001
IS-inf (median, IQR) 11 (5 – 19) 4 (2 – 10) 0.01
IS-inf with cut-off  ≥ 14 (n, %) 51 (39) 5 (12) 0.001
PBA irritability (IQR) 7 (1 – 16) 1 (0 – 5) < 0.001
Any psychiatric disorder b (n, %) 13 (10) 1 (2) 0.10
Major depressive disorder b (n, %) 8 (6) 0 (0) 0.09
Data are presented as n (%), mean (± Standard Deviation (SD)), or median (Inter Quartile Range (IQR)) when appropriate. 
* P-values by chi-square tests for catechorical data, by t-test for independent samples with normal distributions, or non-para-
metric Whitney-U tests.
a Higher education ≥ 12 years of education;
b The presence of psychiatric disorders in the last two weeks are diagnosed with the Composite International Diagnostic In-
terview;
IS-self = Irritability Scale self report; 
IS-inf = Irritability Scale informant report;
PBA = Problem Behaviours Assessment.
table 2. ROC analysis for IS-self scores among 152 HD mutation carriers against three different 
cut-off scores for PBA irritability factor.
PBA irritability cut-off score
> 10 points > 15 points > 20 points
Prevalence of irritability 33% 22% 12%
Optimal IS-self cut-off 13 – 14 13 – 14 13 – 14
Sensitivity 0.58 0.69 0.88
Specificity 0.84 0.81 0.78
AUC 0.80 0.84 0.87
ROC = Receiver Operator Characteristic;
IS-self = Irritability Scale self-report;
PBA = Problem Behaviours Assessment;
AUC = Area Under the Curve.
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their informants, than when others (e.g. family members, friends, or nurses) were informants 
(ICC=0.48). On item level, ICCs were highest for question 12: “Do you yell a lot?” (ICC=0.59, 
P<0.001) and question 1: “Are you easily irritated?” (ICC=0.49, P<0.001), and lowest for question 
7: “Do you insist on having your way?” (ICC=0.28, P<0.001) and question 13: “Are you able to 
control your temper with persons outside the family?” (ICC=0.25, P<0.001) (Figure 1).
Using a cut-off of ≥14 points for both IS-self and IS-informant, 33 (28%) mutation carriers were 
considered irritable according to both IS scales, whereas 60 (50%) mutation carriers were found 
not irritable according to both IS scales. For the remaining 27 (23%) mutation carriers, there 
was disagreement between participants and informants, with the majority of participants (n=18; 
67%) not rating themselves as irritable whereas their informants did.
Presence and severity of irritability in non-carriers and HD mutation carriers
There were important group differences for the IS-self and IS-informant scores among the 43 
non-carriers, 39 pre-motor symptomatic, and 91 motor symptomatic carriers. Both for the IS-
self (P=0.02) and for the IS-informant (P=0.004) there was a trend for increasing irritability 
scores from non-carriers, pre-motor symptomatic, to motor symptomatic carriers (Figure 3B). In 
post-hoc comparisons, non-carriers had lower levels of irritability than both groups of mutation 
carriers.
1-Specificity












figure 2 ROC curves for the irritability scores among 152 HD mutation carriers according to the 
PBA scores.
The blue line is with a cut-off score of 10 points (resulting in 33.1% with irritability). The black line is with cut-off score of 15 
points (resulting in 22.3% with irritability). The red line is with a cut-off score of 20 points (resulting in 12.3% with irritability). 
The open dots indicate the sensitivity and 1 – specificity for a cut-off score of ≥14 points for the irritability scale.
ROC = Receiver Operator Characteristic;
PBA = Problem Behaviours Assessment.
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Correlates of irritability in HD mutation carriers
Table 3 shows that mutation carriers with IS-self ≥14 points had a higher mean CAG repeat 
length (OR=1.16 per CAG triplet, 95%CI=1.02–1.30, P=0.02), a lower TFC score (OR=2.12, 
95%CI=1.02–4.48, P=0.04), and more often used benzodiazepines (OR=2.67, 95%CI=1.20–5.92, 
P=0.02) compared to those with IS-self score <14 points.
In the multivariate logistic regression model, being married/living together (OR=2.85, 
95%CI=1.19–6.83, P=0.02), CAG repeat length (OR=1.20 per CAG triplet, 95%CI=1.04–1.39, 
P=0.01), and the use of benzodiazepines (OR=3.28, 95%CI=1.36–7.89, P=0.008) were indepen-
dent correlates of self-reported irritability (Table 4). Using the same model with the dichotomized 
IS-informant score as the dependent variable, the use of benzodiazepines was the only significant 
independent correlate of irritability (OR=3.54, 95%CI=1.45–8.64, P=0.005).
In sensitivity analyses, being married/living together and the use of benzodiazepines re-
mained independent correlates of self-reported irritability when cut-off scores of IS-self ≥12 






































































































figure 3 Scatter plot representing the intercorrelation between IS-self and IS-inf scores; B. IS-self 
and IS-inf scores (median, IQR) in non-carriers, pre-motor symptomatic carriers and motor symp-
tomatic mutation carriers
A. Univariate regression line is shown, with the intraclass-correlation coefficient (ICC). Dotted lines indicate the cut-off score 
of ≥14 points being indicative of the presence of irritability.
B. The line within the box represents the median and the boundaries of the box represent the interquartile range, while the error 
bars represent the 10th and 90th percentile values (P10 and P90).
* p < 0.05; ** p < 0.005, n.s. = non-significant.
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table 3. Sociodemographic, clinical, and neuropsychiatric characteristics as correlates of irritabil-









Male (n, %) 38 (45) 20 (44) 0.99 (0.48 – 2.05) 0.98
Age, years (mean ± SD) 49 ± 11 48 ± 12 1.00 (0.97 – 1.03) 0.80
Higher level of education a (n, %) 53 (62) 26 (58) 0.83 (0.40 – 1.73) 0.61
Married/living together (n, %) 48 (57) 33 (73) 2.12 (0.96 – 4.66) 0.06
Clinical characteristics
Excessive use of alcohol (n, %) 6 (7) 6 (13) 2.03 (0.61 – 6.69) 0.25
CAG repeat length (mean ± SD) 44 ± 3 45 ± 3 1.16 (1.02 – 1.30) 0.02
TFC < 8.5 points (n, %) 37 (44) 28 (62) 2.12 (1.02 – 4.48) 0.04
UHDRS-m > 19 points (n, %) 38 (45) 26 (58) 1.69 (0.82 – 3.51) 0.16
Use of psychotropics (n, %) 39 (46) 29 (64) 2.14 (1.02 – 3.51) 0.16
   - Antidepressants (n, %) 27 (32) 18 (40) 1.43 (0.68 – 3.04) 0.35
   - Antipsychotics (n, %) 22 (26) 10 (22) 0.82 (0.35 – 1.92) 0.65
   - Benzodiazepines (n, %) 17 (20) 18 (40) 2.67 (1.20 – 5.92) 0.02
Neuropsychiatric characteristics
IS-self (median, IQR) 5 (1 – 8.5) 20 (16.5 – 25) - -
IS-inf (median, IQR) 7 (3 – 12) 19 (12.5 – 27.5) - -
Major depressive disorder b (n, %) 3 (7) 5 (6) 1.15 (0.26 – 5.08) 0.85
MMSE < 28 points (n, %) 46 (54) 30 (67) 1.82 (0.85 – 3.90) 0.13
SDMT 0.08 (1.05) -0.12 (0.90) 0.80 (0.55 – 1.15) 0.23
VFT 0.01 (0.94) -0.02 (1.12) 0.98 (0.68 – 1.40) 0.89
Stroop word 0.14 (1.04) -0.26 (0.86) 0.66 (0.45 – 0.97) 0.11
Stroop colour 0.10 (1.05) -0.19 (0.88) 0.75 (0.51 – 1.08) 0.12
Stroop interference 0.11 (1.06) -0.21 (0.86) 0.73 (0.50 – 1.05) 0.09
Data are presented as n (%), mean (± Standard Deviation (SD)), or median (Inter Quartile Range (IQR)) when appropriate. 
Odds Ratios (ORs) with 95% Confidence Intervals (CI) and p-values by univariate logistic regression. 
*Irritability was considered present if IS-self ≥ 14 points, range 0 – 42 points. 
a Higher education ≥ 12 years of education;
b The presence of major depressive disorder in the last two weeks are diagnosed with the Composite International Diagnostic 
Interview+
TFC = Total Functioning Capacity;
UHDRS-m = Unified Huntington’s Disease Rating Scale motor section;
IS-self = Irritability Scale self-report;
IS-inf = Irritability Scale informant-report;
MMSE = Mini-Mental State Examination;
SDMT = Symbol Digit Modality Test;
VFT = Verbal Fluency Test;




Using the optimal cut off score of IS ≥14 points, the prevalence of irritability in HD mutation 
carriers was 35%. There was a moderate level of agreement between mutation carriers and their 
informants in reporting irritability, with a tendency for mutation carriers to underestimate their 
level of irritability. Being married/living together, a higher CAG repeat length, and the use of 
benzodiazepines were independent correlates of self-reported irritability, whereas the use of ben-
zodiazepines was the only independent correlate of both self-reported and informant-reported 
irritability. 
Since there is no gold standard or formal criteria for the assessment of irritability, any cut-
off point remains somewhat arbitrary. Therefore, we investigated the psychometric properties 
of the IS against the irritability factor of the PBA, an instrument especially developed for the 
assessment of behavioural problems in HD. ROC analysis showed that a cut-off score of ≥14 
points was robust over three PBA cut-off scores. This cut-off score had face validity, since we 
considered it likely that irritable subjects would score at least 1 point on each of the 14 questions 
of the IS. In an earlier study using the IS (n=53), the median IS-self score of 15 points was used 
as a cut-off, defining irritability by IS>15 points; however, that study did not perform a ROC 
analysis (Chatterjee, 2005).
Whereas other (smaller) studies found prevalence rates between 38% and 73% for irritability 
in HD (van Duijn, 2007), we found a rather low prevalence. This may partly be explained by the 
different assessment tools used: the other studies all used non-specific measures for neuropsy-
chiatric symptoms. Besides differences in methodology, sociodemographic and clinical factors 
– like the use of medication – may have contributed to the variation in prevalence of irritability. 
Unfortunately, the only two studies that used the IS do not report prevalence rates of irritability; 
however, these two studies report mean IS-self score of 14 points (Chatterjee, 2005), and 12 
points (Klöppel, 2010), respectively. Furthermore, high levels of hostility may already be present 
before motor symptoms occur (Vassos, 2007), but prevalence of irritability may vary between 






OR (95%CI) p-value OR (95%CI) p-value
Age 1.01  (0.98 – 1.06) 0.48 1.00  (0.96 – 1.04) 0.87
Male 0.98  (0.43 – 2.21) 0.96 1.73  (0.77 – 3.87) 0.18
Married/living together 2.85  (1.19 – 6.83) 0.02 1.75  (0.75 – 4.06) 0.19
CAG repeat length 1.20  (1.04 – 1.39) 0.01 1.14  (0.99 – 1.32) 0.06
Use of benzodiazepines 3.28  (1.36 – 7.89) 0.008 3.54  (1.45 – 8.64) 0.005
Odds Ratios (ORs) with 95% Confidence Intervals (CI) and p-values by multivariate logistic regression.
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disease stages. So far, no significant differences between different disease stages have been found. 
In line with our results
Both previous studies using the IS assessed self-reported and informant-reported irritability. 
In the first study, agreement between (motor symptomatic) mutation carriers and informants re-
garding the presence of irritability (median IS-self >15 points, median IS-informant >16 points) 
was moderate to poor (Chatterjee, 2005). Disagreement was stronger among mutation carriers 
with more intact cognition. The second study assessed irritability in 15 pre-motor symptomatic 
mutation carriers and found no significant differences between self-reported and informant-
reported irritability (Klöppel, 2010). In the present study, we found moderate agreement between 
self-reported and informant-reported irritability. Mutation carriers tended to underestimate 
their level of irritability compared to their informants, since in 18 of the 27 cases with discor-
dant scores, mutation carriers rated themselves as non-irritable (IS <14 points), whereas their 
informants scored above the cut-off. This may indicate denial or a lack of awareness by muta-
tion carriers of their level of irritability. Since we did not ask informants of non-carriers to rate 
the level of irritability, we cannot conclude whether or not this is related to the disease itself. 
On the other hand, caregiver burden may be a source of disagreement between self-reported 
and informant-reported irritability, contributing to a possible overestimation of irritability by 
informants. However, there was a higher level of agreement between IS-self and IS-informant 
scores when spouses/partners rated the IS, than when other informants did so, suggesting a more 
correct estimation by the most intimate informants.
Of all the sociodemographic and clinical characteristics, being married/living together, CAG 
repeat length, and use of benzodiazepines were independent correlates of self-reported irritabil-
ity. While most partners and other caregivers are extremely helpful and important for mutation 
carriers, a higher level of irritability may become more pronounced in intimate relationships that 
may comprise more potential triggers of increased irritability.
The CAG repeat length of mutation carriers was also independently correlated with self-
reported irritability, but not with informant-reported irritability, whereas sensitivity analysis also 
showed that CAG repeat length was not an independent correlate. This is in line with studies that 
found no relationship between CAG repeat length of the HTT gene and any kind of psychopa-
thology (Weigell-Weber, 1996; Zappacosta, 1996; Ravina, 2008; Vassos, 2008).
In the present study use of benzodiazepines was independently correlated to both self-re-
ported and informant-reported irritability. Although benzodiazepines may have been prescribed 
more often to irritable mutation carriers, this cross-sectional study does not allow to draw 
conclusions about causality. Even if the occurrence of irritability in HD is (in part) iatrogenic 
and induced by the use of benzodiazepines, no longitudinal studies have examined the use of 
benzodiazepines and their effects on irritability in HD or other neurodegenerative diseases. 
Nevertheless, it is established that some patients may show paradoxical ‘aggressive’ behaviour 
with benzodiazepines, or behavioural disinhibition (Bond, 1995; Weisman, 1998; Lader, 1991).
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The strength of this study is the use of three different assessment methods for irritabil-
ity, with standardized interviews, in a relatively large HD study population. However, some 
limitations also need to be addressed. First, in the absence of criteria or a gold standard for the 
assessment of irritability, we used the PBA for validation of the IS. Second, only subjects who 
volunteered to participate were included; this may have led to underestimation of the prevalence 
of irritability in HD, since irritable subjects were more likely to refuse to participate. Third, our 
study involved the analysis of cross-sectional data which precludes drawing conclusions about 
the direction of causality. 
In conclusion, we recommend the use of the IS to assess irritability in HD in a standardized 
manner, since this scale proved to be a valid and easy to use instrument. Being married/living 
together and the use of benzodiazepines were independently associated with the presence of ir-
ritability, although only the use of benzodiazepines was also correlated with informant- reported 
irritability and confirmed in the sensitivity analyses. Longitudinal studies are needed to further 
explore these relation- ships. Given the strong association between irritability and the use of 
benzodiazepines, close monitoring of the effect of benzodiazepines is important,  since  clear 
evidence  for  an effective treatment of irritability in HD is still lacking (van Duijn, 2010). 
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Irritability in a prospective cohort of 
huntington’s disease mutation carriers
J.A. Bouwens, E. van Duijn, R.C. van der Mast, R.A.C. Roos, E.J. Giltay




A key symptom of Huntington’s disease (HD), irritability contributes to a decline in functioning 
and to great distress in both patients and their caregivers. To identify mutation carriers prone to 
the development of irritability, this study aimed to investigate the course and temporal relation-
ships between irritability and other neuropsychiatric symptoms. A cohort of 90 mutation carriers 
was followed for two years. Using the Irritability Scale, the incidence of irritability was 23% 
whereas irritability persisted in 70%. An increase in irritability was strongly associated with an 
increase in apathy.  
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IntroduCtIon
Neuropsychiatric symptoms, motor disturbances, and cognitive impairment are core symptoms 
of Huntington’s disease (HD) {1-3}, an autosomal dominant, neurodegenerative disorder 
resulting from an expanded trinucleotide cytosine-adenine-guanine (CAG) repeat in the HTT 
gene on chromosome 4 that codes for the mutant protein huntingtin. Although under normal 
circumstances huntingtin is present ubiquitously, its physiologic role is not fully elucidated. The 
mutant huntingtin probably confers a toxic gain of function, mainly resulting in striatal cell loss. 
The age of onset is widespread, ranging from early childhood to senescence, and is generally 
about 40 years. The duration between diagnosis of motor symptoms and death is around 20 years. 
Neuropsychiatric symptoms, such as irritability, apathy and depressed mood often precede the 
onset of motor symptoms. 
Irritability is a common and key neuropsychiatric symptom of HD {4-6}, which can be 
characterized as a mood state predisposing towards anger, hostile appraisals, impatience, 
intolerance, poorly controlled anger and overt aggression {7;8}. Reduced control over temper 
frequently occurs, resulting in verbal or behavioral outbursts. However, irritability may also be 
present without observable manifestation. Irritability should be distinguished from the DSM-
IV-TR diagnosis of intermittent explosive disorder, since the latter has to meet strict, observable 
criteria and is severe in its phenotype and consequences, whereas irritability may not even be 
visible to an observer. The subjective  experience of irritability may be either brief or prolonged. 
In contrast to justifiable anger, verbal or behavioral outbursts originating from irritable mood 
are nonadaptive, complicate the interaction between the patient and his environment, and are 
always unpleasant for the individual. Irritability can occur early in the course of HD, e.g. up to 10 
years before the onset of motor symptoms {9} and often contributes to a decline in personal and 
occupational functioning {10}. Moreover, irritability of mutation carriers may also cause great 
distress among others, affecting the wellbeing of their families and possibly contributing to the 
necessity of institutionalization {11}.
The prevalence of irritability ranges from 35% to 73%, depending on its definition, the as-
sessment tools used, and the study populations {2;9;12}. In REGISTRY (a European multi-center 
prospective observational study including both manifest and premanifest HD mutation carriers) 
a prevalence of 19.1% of overt disruptive or aggressive behavior among was found among 1468 
mutation carriers {13}. Two prospective studies conducted among 12 pre-motorsymptomat-
ic{14}- and  111 motorsymptomatic{15} HD mutation carriers showed that irritability increased 
over time.
Cross-sectional studies of irritability in motor-symptomatic mutation carriers have found 
associations with other neuropsychiatric symptoms including impulsivity{4}, obsessive com-
pulsive symptoms{16} and suicidal thoughts{17}. Using the 14-item Irritability Scale{18;19}, we 
earlier demonstrated an association between irritability and a low Total Functioning Capacity 
(TFC) score, use of benzodiazepines and more often being married or living together{2}.  
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Since irritability can occur before the onset of motor symptoms, our cohort included both 
pre-motor symptomatic and motor symptomatic mutation carriers. Although cross-sectional 
associations with irritability have been investigated before {2;4;16;17}, to our knowledge, this 
is the first study investigating predictors of incident and persistence of irritability in HD, also 
this is the first study investigating correlates of change in irritability over time. Identification of 
mutation carriers prone to the development and persistence of irritability is required to provide 
adequate treatment and support of HD mutation carriers and their families. Therefore, this study 
investigates the course and temporal relationships between irritability and other neuropsychiat-
ric symptoms in a cohort of 90 HD mutation carriers followed for two years.
methods
Participants
HD mutation carriers and first-degree non-carriers were recruited between May 2004 and 
August 2006 from the outpatient departments of Neurology and Clinical Genetics of Leiden 
University Medical Centre (LUMC) and from a regional nursing home specialized in HD. All 
participants underwent genetic testing and were considered HD mutation carriers with a CAG 
repeat length ≥ 36 repeats. A second measurement was conducted 2 years after the first measure-
ment and a third measurement 2 years thereafter. The study design has been described in detail 
elsewhere{20}.
In the present longitudinal analysis, only the data of mutation carriers who participated 
in the second and third waves of this study are included, because the Irritability Scale {2} was 
introduced halfway during the first measurement. Here, the second wave is referred to as the 
‘baseline measurement’ and the third wave as the ‘follow-up measurement’. A total of 121 muta-
tion carriers completed the Irritability Scale at baseline and  irritability was also assessed in 90 
mutation carriers at follow-up. In total 32 mutation carriers dropped-out (Figure 1).
The study was approved by the medical ethical committee of the LUMC and informed 
consent was obtained from all participants.
Instruments
Assessment of irritability
Irritability was assessed with the self-rated Irritability Scale (Appendix I) that consists of 14 
questions addressing the presence of various phenomena of irritability in the two weeks prior 
to the interview, rated on a 4-point Likert scale {18}. The total sum score of the Irritability Scale 
ranges from 0 - 42 points with higher scores indicating more severe irritability. We used a cut-off 
score of > 13 points as indicative for the presence of irritability; this score was selected based on 
our previous cross-sectional study among 130 HD mutation carriers (largely overlapping with 
baseline data of the current study) where this cut-off provided optimal sensitivity and speci-
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ficity according to ROC analyses {2}. The Cronbach’s alpha of the irritability scale is 0.90 and 
its sensitivity and specificity for detecting irritability in HD mutation carriers is 0.69 and 0.81, 
respectively {2}. We preferred the use of the Irritability Scale over the PBA irritability subscale 
because the Irritability Scale was designed specifically for the assessment of irritability in neu-
rodegenerative disease. Also, the psychometric properties of the Irritability Scale are better than 
those of the PBA irritability subscale (Crohnbachs alpha of 0.90 vs. 0.67, respectively). Since 
no cut-off score for the PBA irritability subscale for the presence of irritability exists, a direct 
comparison is not possible. In our previous study however, we found that with a cut-off score 
on the PBA irritability factor of >15 points, a cut-off score of >13 point on the irritability score 
yielded a sensitivity of 0.69 and a specificity of 0.81.
Assessment of other neuropsychiatric characteristics
The Problem Behaviors Assessment (PBA) was used to assess depression. The PBA is a semi-
structured interview assessing the frequency and severity of 36 potential behavioral problems in 
HD in the month before the interview {4}. The interrater reliability of the Dutch version of the 
PBA is 0.82 for severity scores and 0.73 for frequency scores. We used the symptom factor de-




3 due to severe dysarthria
1 died from suicide
9 died
2 could not be contacted
Baseline:
121 mutation carriers who 
completed the irritability scale 
participated during second wave 
Follow-up:
90 mutation carriers who 
completed the irritability scale 
participated during third wave 
152 mutation carriers 
participated during first wave 
31 (20.4%) drop-out:
18 refused
4 due to severe dysarthria
6 due to severe illness
3 died
figure 1 Flow chart of inclusion of the study participants for the present analysis
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assessed with the Apathy Scale (Appendix II){21}; this scale consists of 14 questions, measuring 
different features of apathy in the 2 weeks before the interview. Caregivers’ information and the 
interviewers’ judgment was included in rating the Apathy Scale, since patients with apathy may 
lack adequate insight into their own symptoms. The Apathy Scale was chosen above the apathy 
factor of the PBA because, although no clear preference arises from the literature, the Apathy 
Scale has better psychometric properties than the PBA apathy subscale (Crohnbach’s alpha 0.89 
vs. 0.84, respectively) and because the former was specifically designed for the assessment of 
apathy.
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics (including alcohol consumption, 
use of psychotropic medication and information about the household) was collected in a standard-
ized manner. Global daily functioning was assessed using the Total Functional Capacity (TFC) 
scale {22} of the Unified Huntington’s Disease Rating Scale (UHDRS) {23}. Motor symptoms 
were assessed using the motor section of the UHDRS (UHDRS-m) by trained neurologists. Mu-
tation carriers with an UHDRS-m confidence level 0-1 were considered pre-motorsymptomatic 
and mutation carriers with UHDRS-m confidence level >1 were considered motorsymptomatic. 
Global cognitive functioning was assessed with  the Mini-Mental State Examination (MMSE) 
{24}. Executive cognitive functioning was assessed with the Symbol Digit Modalities Test 
(SDMT) {25}, the Verbal Fluency Test (VFT) {26} and Stroop tests {27}. Since there is a high level 
of multi-colinearity between most tests (Pearson’s r > 0,80), an aggregate variable for executive 
functioning, ExCog, was constructed by computing the mean of the standardized scores of the 
SDMT, VFT and Stroop tests.
Statistical analyses
Data are presented as n (%), mean (± standard deviation; S.D.) or median (inter-quartile range; 
IQR) when appropriate. Associations between sociodemographic-, clinical- and neuropsy-
chiatric characteristics on the one hand, and incident and persistent irritability on the other 
were determined using univariate logistic regression; odds ratios (ORs) were computed for the 
incidence or persistence of irritability. For the assessment of incident irritability, we identified 
HD mutation carriers without irritability at baseline who were irritable at follow-up. Similarly, 
for the assessment of persistent irritability we identified HD mutation carriers who were irritable 
at baseline and remained irritable at follow-up. A multivariate logistic regression (adjusting for 
sex and age that were entered into the model) was conducted with variables with  p < 0.10 in 
the initial univariate analyses. To assess associations between temporal changes of clinical- and 
neuropsychiatric characteristics on the one hand and irritability on the other, we conducted an 
additional multivariate linear regression analysis. Absolute changes (i.e. delta-values) in all clini-
cal- and neuropsychiatric characteristics between baseline and follow-up were calculated. Linear 
regression analysis was used to assess whether changes in scores of clinical- or neuropsychiatric 
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characteristics as independent variables were associated with changes in the Irritability Scale 
score as the dependent variable. Since our investigation is of a explorative nature and we are not 
aware of known correlates of changes in irritability score, we decided to let a forward selection 
procedure select variables to be included in our final model based upon statistical strength. In the 
final model, the most robust relationships with changes in both irritability and its correlates were 
further analysed using regression analysis, with adjustment for sex, age, and  use of antipsychot-
ics. All tests were two-tailed with p<0.05 denoting statistical significance. The SPSS 20.0 Package 
(SPSS Inc. Chicago, IL)was used for the statistical analyses. 
results
The 90 HD mutation carriers in the current study had an average age of 49 (SD 1.7 years) and 
41 (46%) were males. Their mean TFC score was 8.6 (SD 4.4) and their mean UHDRS-m score 
was 25.3 (SD 2.47). Twenty-five (28%) mutation carriers were pre-motorsymptomatic and 64 
(71%) were motorsymptomatic. UHDRS-m score and motorsymptomatic status was missing in 
1 mutation carrier. The score on the Irritability Scale between baseline and follow-up showed 
no significant change: average increase 1.56 points; 95% confidence interval (CI) -0.23 to 2.89.
At baseline, of the 90 mutation carriers, 33 (37%) were irritable. During the 2-year follow-
up, of the  57 non-irritable HD mutation carriers at baseline, 13 (23%) developed irritability and 
23 (70%) with irritability at baseline were persistently irritable. Compared with mutation carriers 
who completed the follow-up, drop-outs had on average a lower TFC score (5.8 vs. 8.6, p=0.004), 
higher UHDRS-m score (40.4 vs. 25.1, p=0.007), lower MMSE score (23.7 vs. 26.9, p=0.001) and 
worse executive cognitive functioning (-0.53 vs. -0.13, p=0.04); however, there was no difference 
in their Irritability Scale score (10.1 vs. 10.6, p=0.78).
Of the 57 non-irritable HD mutation carriers at baseline, the 13 mutation carriers with 
incident irritability at follow-up had, at baseline, a longer mean CAG repeat length, a higher 
UHDRS-m score, , a lower MMSE score, lower scores on all executive cognitive measures includ-
ing the ExCog variable, and more frequently used benzodiazepines, compared with HD mutation 
carriers who did not develop irritability. In a logistic regression models adjusting for sex and 
age, a longer CAG repeat length, a higher UHDRS-m score, a higher use of benzodiazepines, , a 
lower MMSE score and worse cognitive functioning at baseline were all associated with incident 
irritability at follow-up. (Table 1) Next, we built a final multivariate logistic model adjusting for 
all these significant correlates. In this model, all determinants lost their significance. (Table 1).
There were no significant differences in mutation carriers who showed remission of irritabil-
ity compared to those with persistent (Table 2). In the final model, we adjusted for the use of 
antidepressants, SDMT score and Stroop color score, since these variables had a correlation with 
a p-value<0,10 in the univariate analyses.  In this model, there were no significant associations.
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We analyzed the association between changes in the clinical and neuropsychiatric char-
acteristics with the change in Irritability Scale score. In univariate analyses of these changes, 
we found that an increase in UHDRS-m score, an increase in the Apathy Scale and the use of 
both antipsychotics and of benzodiazepines were associated with an increase in the Irritability 
Scale score over time. Next, we built a final multivariate regression model, comprising sex and 
age at baseline, increase in UHDRS-m score, Apathy Scale score, and the change in use of both 
antipsychotics and of benzodiazepines. We found that the association between change in Ir-
ritability Scale score and change in Apathy Scale score persisted after adjustment for confounders 
(Figure 2). Furthermore the continuous use of antipsychotics was independently associated with 





























































–1 to 0 0 to 1 1 to 2 >2 ≤ –5 –4 to 0 1 to 5 6 to 10 11 to 15 >15
figure 2 Fully adjusted multivariate linear regression of changes in Irritability Scale score on 
changes in apathy as assessed with the PBA apathy factor (left) and the Apathy Scale (right)
table 3 Associations between changes in Irritability Scale score and changes in apathy
Changes in Irritability Scale score
β (95% CI) p-value
Changes in Apathy Scale score
Crude 0.29 (0.08 ; 0.49) 0.01
Adjusted for sex and age 0.29 (0.09 ; 0.49) 0.01
Fully adjusted* 0.41 (0.19 ; 0.62) <0.001
Beta and 95%  confidence interval (CI) derived from linear regression with change in irritability score between baseline and 
follow-up as dependent variable. *Fully adjusted model is also adjusted for increase in motor score, use of benzodiazepines and 
use of antipsychotics. 
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dIsCussIon
In this study, we investigated the course of irritability and its associations with clinical and neu-
ropsychiatric symptoms in a cohort of 90 HD mutation carriers who were followed for 2 years. 
An increasing severity of apathy and the continuous use of antipsychotics were associated with 
increasing severity of irritability over 2 years. 
A recent longitudinal study of neuropsychiatric symptoms followed 111 HD patients for a 
mean of 5 years {15}. At five moments of assessment during follow-up, a minimum of 49% of HD 
patients had one or more symptom of irritability and a maximum of 83% had one or more symp-
tom of irritability. However, the proportions of any of these symptoms cannot be translated easily 
into a prevalence rate of the syndrome of irritability which we used in out analyses. Therefore, 
our incidence of 23% may be a good representation of new-onset irritability at 2-year follow-up 
in individuals with HD.
We found a link between apathy and irritability in HD, reflected by our finding that an in-
crease in apathy coincided with an increase in irritability over a 2-year period. At first glance this 
may seem paradoxical. Apathy is a disorder of motivation that is mainly characterized by a lack of 
goal-directed behavior and cognition and by decreased emotional responsiveness. On the other 
hand, irritability has been characterized as a mood state predisposing toward negative or hostile 
appraisals and to the experience of anger. Although irritability may lead to the overt expression 
of anger, it may also only bother the patient himself without overt expression of irritability. In 
this paradigm, an individual with apathy may well experience irritability, a hypothesis which is 
supported by our study. An explanation for this comorbidity of apathy and irritability in HD 
may be that they have a related pathophysiology since both are caused by neural degeneration 
in subcortical and frontal circuits{28;29}, which is a key feature of HD, in particular the anterior 
cingulate cortex (ACC) and the orbitofrontal cortex (OFC). The ACC plays an important role 
in affect-regulation{30} as well as in decision making{31}. Lesions in the ACC, or in neuronal 
circuitry connected to it, have been associated with apathy{28} as well as behavioral inhibition, 
and aggression{28}. The orbitofrontal cortex is involved in impulse inhibition and lesions in 
the area of the OFC are associated with behavioral disinhibition and emotional lability {28}. In 
addition, hypoactivation of the OFC, as well as the ACC, is associated with impulsive aggres-
sion {29}. Although emotional lability and impulsive aggression may be components of overt, 
observable irritability, these symptoms are absent in irritability that remains out of awareness 
and to our knowledge, the role of subcortical circuitry has not been investigated in this type 
of irritability. Therefore, the comorbidity of apathy and irritability may only be partly due to a 
related pathophysiology. Another factor to be considered is the possibility between construct 
overlap of irritability and apathy as measured by the Irritability and the Apathy Scales respec-
tively. When looking at the items of both scales, there are no obvious similarities or overlapping 
items. Using Spearman’s correlation analyses, we found that the largest correlation coefficient 
was 0,44 between any of the 14 items of the Irritability scale and any of the 14 items of the Apathy 
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Scale. This rather low correlation on any two single items suggest that phenomenological or scale 
reasons cannot account for the associations we found over time between irritability and apathy . 
We found an association between the use of antipsychotics and increasing irritability. Al-
though selective serotonin reuptake inhibitors are recommended as a first-step treatment, anti-
psychotics are frequently prescribed for irritability and related behaviors {32}. Several underlying 
mechanisms may explain the association between the used of antipsychotics and irritability. On 
the one hand, antipsychotics may have been prescribed to treat (among others) irritability, likely 
resulting in confounding by indication as the treated group may on average still be more irritable 
than the untreated group. On the other hand, antipsychotics may have caused irritability or some 
other third factor may underlie the relationship. Furthermore, in some patients antipsychotics 
(both first-generation and second-generation) are known to cause akathisia, a state of psychomo-
tor agitation{33}. Patients experiencing psychomotor agitation associated with akathisia, may 
either become irritable or may have reported positively on certain items on the Irritability Scale 
due to some overlap between the two constructs.
We assessed irritability using the Irritability Scale because this scale was used to assess ir-
ritability in our earlier cross-sectional study{2}. On this scale, our previously validated cut-off 
score of 14 points for the presence of irritability enabled us to investigate the occurrence and 
correlates of incident and persistent irritability. 
The strengths of this study are its prospective design, a relatively large cohort of HD mu-
tation carriers, and the use of validated instruments for the assessments of determinants and 
outcomes. A few limitations should also be addressed. First, although we have validated the use 
of the Irritability Scale in our previous study, there is no gold standard for the assessment of 
irritability. Second, a relatively high number of mutation carriers dropped-out and, therefore, 
did not participate in the current analysis; irritability at follow-up may have been a reason not 
to participate. Selection bias may account for an underestimation of the incidence of irritability 
and for the underestimation of the predictive value of some predictors because of insufficient 
power. Third, we cannot exclude the possibility that cognitive dysfunction in our HD patients has 
distorted the reliability and sensitivity of scales that assessed of neuropsychiatric characteristics.
In conclusion, we found an unexpected association between irritability and apathy. HD 
mutation carriers that become more apathetic over time also seem to become more irritable. 
The association between irritability and apathy may imply a shared underlying pathophysiol-
ogy between these neuropsychiatric symptoms in HD. Since apathy may mask irritability, we 
recommend asking mutation carriers with apathy and their caregivers about the symptoms of 
irritability in order to provide adequate support and treatment.
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Chapter 4
acute-phase proteins in relation to neuropsychiatric symptoms 
and use of psychotropic medication in huntington’s disease
J.A. Bouwens, A.A. Hubers, E. van Duijn, C.M. Cobbaert, R.A.C. Roos, 





Activation of the innate immune system has been postulated in the pathogenesis of Huntington’s 
disease (HD). We studied serum concentrations of C-reactive protein (CRP) and albumin as 
positive and negative acute-phase proteins in HD. Multivariate linear and logistic regression 
was used to study the association between acute-phase protein levels in relation to clinical, 
neuropsychiatric, cognitive, and psychotropic use characteristics in a cohort consisting of 122 
HD mutation carriers and 42 controls at first biomarker measurement, and 85 HD mutation 
carriers and 32 controls at second biomarker measurement. Significant associations were found 
between acute-phase protein levels and Total Functioning Capacity (TFC) score, severity of 
apathy, cognitive impairment, and the use of antipsychotics. Interestingly, all significant results 
with neuropsychiatric symptoms disappeared after additional adjusting for antipsychotic use. 
High sensitivity CRP levels were highest and albumin levels were lowest in mutation carriers 
who continuously used antipsychotics during follow-up versus those who had never used anti-
psychotics (mean difference for CRP 1.4 SE mg/L; P = 0.04; mean difference for albumin 3 SE 
g/L; P < 0.001). The associations found between acute-phase proteins and TFC score, apathy, and 
cognitive impairment could mainly be attributed to the use of antipsychotics. This study provides 
evidence that HD mutation carriers who use antipsychotics are prone to develop an acute-phase 
response.
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IntroduCtIon
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease, characterized 
by motor abnormalities, cognitive dysfunction, and neuropsychiatric symptoms1 including 
depressed mood,2 apathy,3;4 and irritability.5 Although the mean age of onset is 40 years, there is 
a wide range in age at onset, severity, and symptomatology of HD. HD is caused by an expanded 
trinucleotide cytosine-adenine-guanine (CAG) repeat on chromosome 4 coding for the mutant 
huntingtin protein.6 Although the genetic defect has been elucidated, its role in the pathogenesis 
of HD remains unclear.
There is increasing evidence that the immune system may be involved in the pathogenesis 
of HD. Increased activation of components of the innate and adaptive immune systems has been 
found in the central nervous system (CNS)7-9 and peripheral tissues of HD patients.10 In par-
ticular, increased concentrations of tumor necrosis factor (TNF)-α and interleukin (IL)-6, have 
been found in plasma of HD mutation carriers when compared to controls.11 Physiologically, 
TNF-α and IL-6 are pro-inflammatory cytokines which are released in the bloodstream as part 
of the acute-phase response.12;13 C-reactive protein (CRP) synthesis is upregulated in the liver 
under regulation of IL-6,14 whereas the synthesis of other proteins such as albumin is down-
regulated. Since in the acute-phase response CRP levels increase, CRP can be thought of as a 
positive acute-phase protein and since albumin levels decrease, albumin can be thought of as a 
negative acute-phase protein.
Previously, CRP levels have been reported to be significantly increased in HD mutation 
carriers in advanced disease stage when compared to controls.15 Levels of CRP were significantly 
higher in a group of 13 HD mutation carriers when compared to 10 healthy controls. Also, 
levels of CRP were higher in HD mutation carriers with more advanced disease.16 A large set of 
markers for inflammation and innate immunity was measured in a recent study that included 
two cohorts comprising 81 HD mutation carriers and 40 controls, but none of the more than 
20 plasma constituents were significantly different between the groups.17 Nevertheless, post-hoc 
tests revealed significantly lower CRP levels in HD mutation carriers with early disease versus 
controls, whereas premanifest HD had similar levels compared with controls.
In various other populations, there are reports indicating an association between CRP18-20 
and albumin21-24 levels on the one hand, and both cognitive dysfunction and neuropsychiatric 
symptoms on the other hand. In a systematic review assessing the association between CRP level 
and stroke, cognitive disorders, and depression,18 raised CRP concentrations were associated 
with cognitive decline and increased risk of dementia. Low albumin levels were associated with 
cognitive dysfunction in two large population-based studies of the non-demented elderly.21;22 
In a large longitudinal study with 73,131 participants from the general population, a positive 
association was found between CRP levels and depressive symptoms.19 Also, a meta-analysis 
showed a positive correlation between CRP levels and depression (d = 0.15; 95% confidence 
interval [CI] 0.10 – 0.21).20 Low albumin levels were found in depressed patients compared to 
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healthy controls.23;24 Cross-sectionally, a significant association was found between CRP levels 
and apathy in elderly individuals.25 Longitudinally, however, higher CRP levels were not associ-
ated with an increased risk of apathy in individuals aged 85 years and over.26
Antipsychotics are frequently prescribed for symptomatic treatment of chorea and neu-
ropsychiatric symptoms in HD.27 It has become apparent that the use of antipsychotics may 
adversely affect CRP levels.23;28;29 In addition, weight gain is a well-known side-effect of treatment 
with atypical antipsychotics,30 which is associated with an increase of IL-6 and other proteins 
associated with low-grade inflammation.31 The effects of antipsychotics on levels of albumin have 
not been thoroughly studied, although serum albumin was decreased in a group of schizophrenic 
patients when compared with healthy controls. However, no significant effect of the use of anti-
psychotics was demonstrated.32
This study aims to investigate CRP levels as a positive acute-phase protein and albumin 
levels as a negative acute-phase protein in relation to clinical, neuropsychiatric, and cognitive 
characteristics in a cohort of HD mutation carriers. For this, we took into account factors that 
might have confounded or otherwise influenced these associations, in particular the use of 
antipsychotics. Our hypothesis was that, with disease progression, inflammatory activity would 
increase leading to higher CRP levels and lower albumin levels, associated with a higher preva-
lence of cognitive impairment and neuropsychiatric symptoms.
experImental proCedures
Population
Between May 2004 and August 2006, 152 HD mutation carriers and 56 controls were recruited 
for participation. Sources for recruitment were the outpatient departments of Neurology and 
Clinical Genetics of the Leiden University Medical Center (LUMC) and a regional nursing home 
specialized in care for HD patients. Besides HD mutation carriers, verified first-degree non-
carriers participated in the study as controls. The study design is described in detail elsewhere.33 
A second measurement was conducted two years after the baseline visit (including 128 mutation 
carriers and 42 controls) and a third measurement two years thereafter (including 94 HD muta-
tion carriers and 32 controls). Blood samples suitable for the determination of high sensitivity 
CRP (hsCRP) and albumin levels were available at the second and the third measurement. Since 
6 participants did not give blood at the first biomarker measurement (defined as t1) they were ex-
cluded from the analyses, which resulted in 122 mutation carriers at t1. At the second biomarker 
measurement (defined as t2), 9 participants did not give blood, which resulted in 85 mutation 
carriers at t2.
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Sample withdrawal and biochemical analyses
At t1 and t2 EDTA blood was withdrawn between the years 2008 and 2012 and subsequently 
stored at -80 ºC within 2 h. Blood samples were stored until measurement of hsCRP and albumin 
levels in the fall of 2012. hsCRP was determined in EDTA plasma with an IFCC standardized 
method (Cat. no. 04628918190) on a COBAS INTEGRA 800 analyzer from Roche Diagnostics, 
according to the instructions of the manufacturer. The expected reference range for hsCRP in 
adult males and females is < 5 mg/L. Between-run coefficients of variation (CVs) during the study 
period (12 runs) were 5.8% at 4.09 mg/L, and 5.7% at 12.81 mg/L. Albumin in EDTA plasma was 
determined with an IFCC standardized method (Cat. no. 11970909216) on Modular P systems 
from Roche Diagnostics, using a BCG-based colorimetric assay with endpoint detection. This 
method has been standardized against the CRM 470 reference preparation. The reference range 
for serum albumin in adult males and females is 34–48 g/L. CVs during the study period (7 runs) 
were 2.94% at 37.5 g/L and 1.01% at 55.0 g/L.
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics, including the potential con-
founders like current smoking, high alcohol consumption (defined as drinking more than 14 
standardized units of alcohol a week), body weight and height, and medication use, was collected 
using a standardized interview. Use of antipsychotics was divided in different categories: typical 
antipsychotics, atypical antipsychotics, and tiapride. Tiapride was considered a separate category 
as it was used by many participants and cannot be classified unambiguously within one of the 
other categories. The estimated duration of disease was calculated by the current age minus the 
estimated age of onset according to the equation of Vassos.34 The Total Functional Capacity 
(TFC) scale of the Unified Huntington’s Disease Rating Scale (UHDRS)35 was used to assess 
global daily functioning and disease stage.36 Total scores range from 0 to 13 points, with higher 
scores indicating better global functioning.37
Motor functioning was assessed by a trained neurologist using the motor scale of the UH-
DRS.35 Total scores range from 0 to 124, with higher scores indicating worse motor functioning. 
The diagnostic Confidence Level (CL) of the UHDRS motor scale was used to define mutation 
carriers as pre-motor symptomatic (CL 0 or 1 point) or motor symptomatic (CL 2 to 4 points).
Neuropsychiatric characteristics
Neuropsychiatric characteristics were assessed by the Dutch version of the Problem Behaviours 
Assessment (PBA),38 a semi-structured interview, assessing the frequency and severity of 36 
potential behavioral problems in HD. The inter-rater reliability of the Dutch version of the PBA 
is 0.82 for severity scores and 0.73 for frequency scores.39 In this study we used symptom factors 
that were previously estimated by factor analysis of the PBA, which resulted in three factors: 
apathy (range 0–64), irritability (range 0–80), and depression (range 0–80).39 Additionally, sui-
cidality was assessed with the PBA38 by multiplying the severity and frequency score of the item 
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‘suicidal ideation’. As done before, a total score > 1 point on this item was used to characterize 
the presence of suicidality.40
Cognitive characteristics
The Mini-Mental State Examination (MMSE) was used to assess global cognitive functioning. 
Total scores range from 0 to 30 points, with higher scores indicating better global cognitive 
functioning.41 The cognitive scales of the UHDRS,35 including the Verbal Fluency Test (VFT),42 
the Symbol Digit Modalities Test (SDMT),43 and the Stroop tests,44 were used to assess executive 
cognitive functioning. For all cognitive scales, higher scores indicate better executive function-
ing. The ExCog, a composite variable obtained by averaging the standardized z-scores of the 
other executive cognitive subscales, was used as a measure for executive cognitive functioning.
Statistical analyses
Data are presented as n (%), mean (± standard deviation [SD]), mean (95% CI), or median 
(interquartile range [IQR]) when appropriate. 
Because of their positively skewed distribution, hsCRP levels were log transformed before 
being used in statistical analyses. Characteristics of HD mutation carriers and controls at t1 were 
compared by chi-squared tests for categorical data, t-tests for independent samples with normal 
distributions, or non-parametric Whitney-U tests for continuous variables without normal 
distributions.
Associations between hsCRP and albumin levels and clinical, neuropsychiatric, and cogni-
tive characteristics were determined by linear regression analysis for continuous outcomes and 
logistic regression analysis for dichotomous outcomes. Apart from the crude model, we adjusted 
in the first multivariate models for the potential confounders sex, age, body mass index (BMI), 
smoking, and alcohol consumption at t1. Since previous literature indicated that the use of 
antipsychotics may affect CRP levels,23;28;29 a second model was built, including the variables 
from the adjusted model and the use of antipsychotics. Furthermore, analysis of covariance 
(ANCOVA) was used to compare acute-phase protein levels between participants who did not 
use antipsychotics, participants who started using antipsychotics during the study period, and 
participants who continuously used antipsychotics, with adjustment for sex, age, BMI, smoking, 
and alcohol consumption at t1. In an additional model comparing acute-phase protein levels at 
t2 between the different groups, we additionally adjusted for acute-phase protein levels at t1. As 
a sensitivity analysis, this ANCOVA was repeated without participants whose hsCRP level was 
above 10 mg/L, due to their possible association with acute infectious diseases. Since almost all 
participants who used antipsychotics were in later disease stages and disease stage may also be 
related to the acute-phase response, we performed a sensitivity analysis which only included the 
participants with a disease stage > 2 (TFC score < 7) at t1. As previous research showed that the 
effect of antipsychotic use on CRP levels is different for different kinds of antipsychotics,28 we 
performed a mixed model analysis (i.e., multilevel regression analysis) with adjustment for age, 
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sex, BMI, smoking, and alcohol consumption at t1, to evaluate associations between the different 
categories of antipsychotics and acute-phase protein levels.
A p-value < 0.05 was considered statistically significant. p-Values presented were not cor-
rected for multiple comparisons, since we interpreted the overall pattern of diminishing effect 
sizes and p-values after additional adjustment for the use of antipsychotics in multivariable 
models. SPSS version 20.0 was used.
results
Characteristics of mutation carriers versus controls
At t1, mutation carriers more often used psychotropic medication, had higher scores on the 
apathy, irritability, and depression factors of the PBA and worse scores on all cognitive tests, 
compared with controls (Table 1). When comparing acute-phase proteins, the hsCRP level of 
the mutation carriers at t1 was non-significantly higher in mutation carriers compared with 
controls (Table 1). At t2, the hsCRP level of mutation carriers was significantly higher compared 
with controls (mean: 1.94; 95% CI: 1.50–2.51 versus 0.99; 95% CI: 0.64–1.52, respectively; p = 
0.002) (data not shown). There was a significant trend of increasing hsCRP levels across increas-
ing disease stages at t1 and t2 (Suppl. Table 1). The albumin level of the mutation carriers was 
significantly lower compared with controls, both at t1 (Table 1) and t2 (mean: 46.4; 95% CI: 
45.8–47.1 versus 47.6; 95% CI: 46.5–48.7, respectively; p = 0.03) (data not shown). However, after 
correction for potential confounders (sex, age, BMI, smoking, and alcohol consumption) only 
the hsCRP level at t2 remained significantly different between mutation carriers and controls. 
There was a significant trend of decreasing albumin levels across increasing disease stages at t1 
and t2 (Suppl. Table 1).
Associations between acute-phase proteins and clinical characteristics at t1
Serum hsCRP level was significantly associated with TFC score, apathy score (Table 2), benzodi-
azepine use, and antipsychotic use (Table 3). Using multivariate linear regression analyses, with 
adjustment for potential confounders, the hsCRP level remained significantly associated with 
apathy score, Stroop interference test, and ExCog (Table 2). However, after additional adjustment 
for use of antipsychotics, all these associations lost their statistical significance (Tables 2 and 3). 
Serum albumin level was independently associated with TFC score, apathy score, SDMT 
score, the Stroop test scores, ExCog (Table 2), MMSE score, use of benzodiazepines, and use of 
antipsychotics (Table 3). Likewise, after additional adjustment for use of antipsychotics, all these 
associations lost their statistical significance (Tables 2 and 3). 
Chapter 4
54
table 1. Characteristics of HD mutation carriers and controls at first biomarker measurement (t1).
Mutation carriers Controls p-valuea
n = 122 n = 42
Sociodemographic characteristics
Male gender 54 (44%) 19 (45%) 0.91
Age (years) 49.2 ± 11.5 41.0 ± 11.2 <0.001
BMI (kg/m2) 25.6 ± 5.1 25.1 ± 4.3 0.62
Smoking 30 (26%) 12 (29%) 0.73
High alcohol consumption 11 (9%) 1 (2%) 0.30
Biological characteristics
Albumin (mean in g/L, 95% CI) 47.1 (46.5 – 47.7) 48.5 (47.6 – 49.5) 0.01
hsCRPb (mean in mg/L, 95% CI) 1.49 (1.20 – 1.86) 1.23 (0.85 – 1.79) 0.39
Clinical characteristics
CAG repeats (number) 44.1 ± 3.2 21.6 ± 4.2 <0.001
Estimated disease duration (years) 3.8 ± 11.4 NA NA
TFC score 8 (3 – 13) 13 (13 – 13) <0.001
UHDRS motor score 19 (5 – 48) NA NA
Pre-motor symptomatic 33 (28%) NA NA
Antidepressant use 44 (36%) 1 (2%) <0.001
Benzodiazepine use 25 (21%) 0 (0%) 0.001
Antipsychotic use 35 (29%) 0 (0%) <0.001
Neuropsychiatric characteristics
PBA apathy factor score 2 (0 – 18) 0 (0 – 0) <0.001
PBA irritability factor score 4 (0 – 15) 0 (0 – 2) <0.001
PBA depression factor score 4 (0 – 12) 0 (0 – 6) 0.04
PBA suicidality 14 (12%) 1 (2%) 0.08
Cognitive characteristics 
MMSE score 28 (24 – 29) 29 (29 – 30) <0.001
SDMT score 35 (12 – 50) 53 (47 – 58) <0.001
VFT score 20 (10 – 30) 29 (25 – 37) <0.001
Stroop colour score 50 (33 – 71) 76 (69 – 87) <0.001
Stroop word score 71 (41 – 98) 99 (99 – 100) <0.001
Stroop interference score 29 (16 – 40) 44 (39 – 47) <0.001
ExCog -0.20 ± 0.9 0.68 ± 0.3 <0.001
Data are presented as n (%), mean (± SD), or median (interquartile range [IQR]), unless otherwise specified.
BMI denotes Body Mass Index; hsCRP, high sensitivity C-reactive protein; CI, confidence interval; NA, applicable; TFC, total 
functional capacity; UHDRS, Unified Huntington’s Disease Rating Scale; PBA, Problem Behaviour Assessment; MMSE, Mini 
Mental State Examination; SDMT, Symbol-Digit Modalities Test; VFT, Verbal Fluency Test.
a p-Values by chi-squared test for categorical data, by t-test for independent samples with normal distributions, or non-para-
metric Whitney-U tests for independent samples without normal distributions.
b Because of its skewed distribution, hsCRP was log transformed before the analyses.
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Associations between acute-phase proteins and clinical characteristics at t2
When analyzing cross-sectional associations between hsCRP and albumin levels on the one hand 
and clinical, neuropsychiatric, and cognitive characteristics on the other hand at t2, similar as-
sociations were found as at t1. Once more, significant associations disappeared after additionally 
adjusting for antipsychotic use (data not shown).
table 2. Cross-sectional relationships between acute-phase proteins and continuous clinical, neu-
ropsychiatric, and cognitive characteristics in 122 HD mutation carriers at first biomarker mea-
surement (t1).
Crude Model 1a Model 2a
hsCRPb Albumin hsCRPb Albumin hsCRPb Albumin
Clinical characteristics
CAG repeats 0.01 0.11 0.17 -0.04 0.15 0.00
Estimated disease duration 0.12 -0.27** 0.10 -0.04 0.09 -0.01
TFC scoreb -0.19* 0.38*** -0.15 0.28** -0.07 0.16
UHDRS motor scoreb 0.12 -0.24** 0.14 -0.14 0.09 -0.05
Neuropsychiatric characteristics
PBA apathy factor scoreb 0.21* -0.29*** 0.22* -0.24* 0.15 -0.12
PBA irritability factor scoreb 0.06 -0.05 0.02 -0.10 0.02 -0.11
PBA depression factor scoreb 0.09 0.04 0.08 0.02 0.07 0.04
Cognitive characteristics
SDMT scoreb -0.13 0.31*** -0.16 0.20* -0.08 0.06
VFT scoreb -0.12 0.24** -0.17 0.18 -0.11 0.07
Stroop Word Test scoreb -0.14 0.27** -0.19 0.18* -0.12 0.08
Stroop Color Test scoreb -0.13 0.32*** -0.18 0.24* -0.10 0.11
Stroop Interference Test 
scoreb
-0.13 0.32*** -0.22* 0.24* -0.14 0.10
ExCog -0.14 0.30** -0.20* 0.22* -0.12 0.09
Data are standardized betas. Analyses performed by linear multivariate regression analyses. Model 1: adjusted for sex, age, BMI, 
smoking, and alcohol consumption at t1; Model 2: additional adjustment for use of antipsychotics at t1.
hsCRP denotes high sensitivity C-reactive protein; TFC, total functional capacity; UHDRS, Unified Huntington’s Disease Rat-
ing Scale; PBA, Problem Behaviour Assessment; SDMT, Symbol-Digit Modalities Test; VFT, Verbal Fluency Test; BMI, Body 
Mass Index.
*p < 0.05.
** p < 0.01. 
*** p < 0.001.
a n=115 mutation carriers because of missing values.
b Because of its skewed distribution, hsCRP, TFC score, UHDRS motor score, PBA factor scores, SDMT score, VFT score, and 
Stroop scores were log transformed before the analyses.
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Use of antipsychotics and acute-phase proteins
When comparing mutation carriers who started using antipsychotics during the study period 
with mutation carriers who did not use antipsychotics during the study period, the hsCRP level 
of starters at t1 was not significantly different from non-users. At t2, however, the hsCRP level of 
starters had increased and was higher compared with non-users, although statistical significance 
disappeared after adjustment for the hsCRP level at t1 (Figure 1 and Suppl. Table 2). Compared 
with non-users, mutation carriers who continuously used antipsychotics had significantly higher 
hsCRP levels at both measurements and also had a larger increase in hsCRP level between the 
two measurements (Figure 1 and Suppl. Table 2). 
Likewise, serum albumin levels of antipsychotic starters tended to decline, but the com-
parison with non-users was not significant at both measurements (Figure 1 and Suppl. Table 2). 
Albumin levels of continuous users were significantly lower compared with non-users at both t1 
and t2, even after adjustment for the albumin level at t1 (Figure 1 and Suppl. Table 2). 
After excluding participants with an hsCRP level above 10 mg/L, differences in hsCRP and 
albumin levels between non-users and starters and between non-users and continuous users at 
t1 persisted. At t2, continuous users had significantly more often hsCRP levels above 10 mg/L 
than non-users (21.1% versus 4.1%, respectively; p = 0.03). hsCRP levels remained higher and 
albumin levels lower in starters and continuous users compared with non-users, although the 

















































figure 1 High sensitivity C-reactive protein (hsCRP) and albumin levels in controls and mutation 
carriers. For hsCRP levels the adjusted, backtransformed geometric mean values and for albumin 
the adjusted mean values are presented. Error bars represent the 95% confidence intervals. Muta-
tion carriers were categorized according to antipsychotic (AP) usage into those: (1) who did not use 
AP at either time points; (2) who started the use of AP; and (3) who continuously used AP at both 
time points. Data were analyzed using analyses of covariance (ANCOVA) adjusting for sex, age, 
body mass index, smoking, and alcohol use at first biomarker measurement. 
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When repeating the analysis only in participants with a disease stage > 2, the differences 
that were found between continuous users and non-users at both t1 and t2 were comparable to 
those in the original analysis, while this was not the case for the differences between starters and 
non-users.
Using linear mixed models analyses, with adjustment for potential confounders, all three cat-
egories of antipsychotics were positively associated with hsCRP levels. Effect estimates indicated 
a rather similar effect sizes for typical antipsychotics (n = 32; ß = 0.42), atypical antipsychotics 
(n = 26; ß = 0.25), and tiapride (n = 28; ß = 0.30). Likewise, inverse associations were found with 
albumin: typical antipsychotics (n = 32; ß = -0.47), atypical antipsychotic (n = 26; ß = -0.53), and 
tiapride (n = 28; ß = -0.36) (data not shown).
dIsCussIon
We found strong associations between the use of antipsychotics and an elevated acute-phase 
response in HD. Other associations between hsCRP and albumin levels on the one hand and 
table 3. Cross-sectional relationships between acute-phase proteins and dichotomous clinical, 
neuropsychiatric, and cognitive characteristics in 122 HD mutation carriers at first biomarker mea-
surement (t1).
Crude Model 1a Model 2a
hsCRPb Albumin hsCRPb Albumin hsCRPb Albumin
Clinical characteristics
Pre-motor symptomatic 1.20 0.92 1.31 0.97 1.18 1.05
Antidepressant use 1.15 0.88* 0.88 0.92 0.74 0.98
Benzodiazepine use 1.47* 0.75*** 1.21 0.79* 1.08 0.84
Antipsychotic use 1.64** 0.72*** 1.54 0.77** n/a n/a
Neuropsychiatric characteristics
PBA suicidality 1.05 0.83* 0.92 0.83 0.80 0.86
Cognitive characteristics
MMSE score 0.79 1.18** 0.71 1.19* 0.78 1.13
Data are odds ratios. Analyses performed by logistic multivariate regression analyses. Model 1: adjusted for sex, age, BMI, 
smoking, and alcohol consumption at t1; Model 2: additional adjustment for use of antipsychotics at t1.
hsCRP denotes high sensitivity C-reactive protein; PBA, Problem Behaviour Assessment; MMSE, Mini Mental State Examina-
tion; BMI, Body Mass Index.
*p < 0.05.
** p < 0.01. 
*** p < 0.001.
a n=115 mutation carriers because of missing values.
b Because of its positively skewed distribution, hsCRP was log transformed before the analyses.
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TFC score, apathy, and cognitive impairment on the other hand, disappeared when adjusting 
for the use of antipsychotics. Also, mutation carriers who continuously used antipsychotics had 
significantly higher hsCRP levels and lower albumin levels compared with mutation carriers who 
did not use antipsychotics during the study period.
Increases in CRP levels have previously been found in HD mutation carriers when compared 
to controls and one study also found a correlation between disease stage and CRP levels.15;16 In 
contrast, we only found a significant increasing trend of CRP across increasing disease stages but 
no differences in CRP levels between the whole group of HD mutation carriers and controls. The 
relatively low number of HD mutation carriers in more advanced disease stages in our cohort 
may have accounted for this finding. This idea is in line with the finding of a study reporting that 
premanifest and early-stage HD mutation carriers, who are in lower disease stages, had similar 
or lower CRP levels respectively, when compared with controls.17
Previous publications offer several mechanisms that could explain our finding of an elevated 
acute-phase reaction in mutation carriers who used antipsychotics. First, the use of antipsy-
chotics may cause symptoms associated with the metabolic syndrome which in turn induces an 
acute-phase response. Atypical antipsychotics are strongly associated with the development of 
metabolic syndrome, which is characterized by abdominal obesity, dyslipidemia, hypertension, 
and insulin resistance. Obesity,45 dyslipidemia,31 and insulin resistance46 may induce low-grade 
inflammation reflected in increased CRP levels. In rats, it has been shown that treatment with 
olanzapine induces weight gain and increased adipose tissue. In addition, the adipose tissue of 
olanzapine-treated rats had become infiltrated with macrophages and there was a 2-fold increase 
in the expression of the TNF-α, both indicative of low-grade inflammation.47 Second, the use 
of antipsychotics may directly induce low-grade inflammation through their hepatic impact 
since antipsychotics are eliminated predominantly by hepatic metabolism. In the CATIE trial,28 
increased CRP levels were indicative of having more signs of the metabolic syndrome but were 
also independently associated with the use of atypical antipsychotics, in particular olanzapine. 
In a smaller open-label study, with 111 patients randomized to haloperidol, olanzapine, and ris-
peridone, patients on haloperidol showed the strongest increase in CRP levels after three months 
of treatment.29
Since the effects in our study were largely unaffected by adjustment for BMI, we assume that 
the use of antipsychotics directly induced an acute-phase response. Atypical antipsychotics are 
most often implicated in induction of inflammation but in our mixed-model analyses, we did not 
find a differential role for atypical antipsychotics, typical antipsychotics, and tiapride. Therefore 
these groups were combined.
Immune activation in HD is widespread48 and is known to positively correlate with disease 
stage. IL-6, a cytokine that plays a main role in the innate immune response, was shown to be 
up-regulated both centrally and peripherally in HD.11 One of its functions is to initiate the acute-
phase response, thus subsequently increasing the synthesis of CRP while decreasing albumin 
levels. Neuroinflammation leads to neuronal degeneration through several mechanisms, and 
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neuronal degeneration in the striatum is one of the key histopathological features of HD that is 
associated with movement abnormalities, cognitive and several neuropsychiatric symptoms. Our 
findings may therefore also be explained by reverse causation meaning that neuroinflammation 
has caused movement abnormalities and neuropsychiatric symptoms, which in turn has led to 
the prescription of antipsychotics.
Although influenced by the use of antipsychotics, we did find associations between levels of 
acute-phase proteins and several clinical variables. We found an association for TFC, apathy, and 
cognitive impairment. Previous studies in non-HD populations also found associations between 
levels of acute-phase proteins and both apathy25 and cognitive impairment.18;21;22 In contrast to 
our study, these studies did not investigate the role of antipsychotics in these associations. In 
our study, the elevated acute-phase reaction was strongly associated with the use of antipsychot-
ics and all associations between acute-phase proteins and clinical variables disappeared when 
adjusting for antipsychotics. As previously argued, we hypothesize that the use of antipsychotics 
induced an acute-phase response which in turn was associated with several neuropsychiatric 
symptoms and cognitive impairment. But associations between acute-phase proteins on the one 
hand and TFC, apathy, and cognitive impairment on the other hand, may have been confounded 
by the use of antipsychotics. Alternatively, confounding by indication may explain our results.
To our knowledge, this is the first study investigating the role of the acute-phase response 
in the occurrence of neuropsychiatric symptoms and cognitive dysfunction in HD. Strengths of 
this study are the use of a comparison group (consisting of first-degree non-carriers), the use 
of validated measurement tools in a standardized interview, and the adjustment for potential 
confounders, including antipsychotic use, in the analyses. There are several limitations that war-
rant discussion. Since inflammation is associated with the neurodegenerative process in HD, 
relationships found in this study might not be generalized to other disorders and the general 
population. Given the observational rather than experimental nature of our study, it is impos-
sible to make causal inferences about our findings.
Future research on the role of antipsychotic use on the acute-phase reaction is necessary, 
both in HD and in other populations. We found strong evidence for a role of antipsychotics in 
inducing an acute-phase response in HD mutation carriers. Although we could not make infer-
ences regarding the direction of causation, HD mutation carriers who receive antipsychotics may 
be prone to the development of low-grade inflammation, which may subsequently increase their 
risk of cardiovascular morbidity, lower functioning capacity, apathy, and cognitive dysfunction.
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supplementary table 1. Levels of hsCRP and albumin at different disease stages according to TFC 
score at t1 and t2
Disease stage according to 
TFC score*




•	 No. of mutation carriers 52 19 25 10 16
•	 Albumin (g/L) 48.2 ± 2.8 47.0 ± 2.3 47.1 ± 2.9 46.0 ± 3.3 44.2 ± 4.2 <0.001
•	 hsCRP (mg/L) 2.3 ± 3.3 2.4 ± 2.9 4.2 ± 5.2 3.2 ± 1.8 5.5 ± 6.1 0.02
•	 Antipsychotic use 1 (2%) 4 (21%) 13 (52%) 7 (70%) 10 (63%) <0.001
t2:
•	 No. of mutation carriers 33 16 22 7 7
•	 Albumin (g/L) 47.5 ± 3.7 46.9 ± 2.5 46.5 ± 2.5 43.2 ± 0.8 43.2 ± 3.8 <0.001
•	 hsCRP (mg/L) 2.4 ± 2.7 5.4 ± 12.3 4.1 ± 4.9 3.3 ± 2.1 17.6 ± 25.8 0.01
•	 Antipsychotic use 0 (0%) 5 (31%) 15 (68%) 7 (100%) 7 (100%) <0.001
Data are numbers, means ± standard deviation (SD), or numbers (percentages) where appropriate.
hsCRP denotes high sensitivity C-reactive protein; TFC, total functional capacity.
*: Stage I: TFC>10, Stage II: 6<TFC<11, Stage III: 2<TFC<7, Stage IV: 0<TFC<3, Stage V: TFC=0. 
P-value for trend computed by linear regression analysis or chi-squared test, linear by linear term.
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supplementary table 2. Levels of acute-phase proteins in mutation carriers according to antipsy-
chotic use.
Mutation carriers not 
using antipsychotics










high sensitivity C-reactive protein (mg/l)a:
    First biomarker measurement 
    - Crude 1.10 (0.76 – 1.58) 1.67 (0.79 – 3.50) 0.28 1.93 (1.27 – 2.93) 0.04
    - Model 1b 1.08 (0.77 – 1.50) 1.83 (1.01 – 3.32) 0.13 1.71 (1.03 – 2.82) 0.15
    Second biomarker measurement 
    - Crudec 1.40 (0.99 – 1.98) 2.57 (1.29 – 5.12) 0.10 3.61 (2.02 – 6.46) 0.005
    - Model 1d 1.37 (0.97 – 1.94) 2.88 (1.54 – 5.40) 0.04 3.00 (1.68 – 5.37) 0.03
    - Model 2e 1.47 (1.07 – 2.01) 2.31 (1.29 – 4.15) 0.18 2.82 (1.67 – 4.77) 0.04
albumin (g/l):
    First biomarker measurement
    - Crude 48.1 (47.4 – 48.8) 47.2 (45.3 – 49.1) 0.27 45.3 (44.1 – 46.5) <0.001
    - Model 1b 48.0 (47.2 – 48.8) 47.2 (45.8 – 48.7) 0.38 45.7 (44.5 – 46.9) 0.003
    Second biomarker measurement
    - Crudec 47.6 (46.9 – 48.3) 46.4 (45.0 – 47.9) 0.10 44.0 (42.6 – 45.4) <0.001
    - Model 1d 47.7 (46.9 – 48.5) 46.4 (45.0 – 47.8) 0.10 44.1 (42.8 – 45.4) <0.001
    - Model 2e 47.4 (46.8 – 48.0) 47.0 (45.8 – 48.2) 0.55 44.7 (43.6 – 45.7) <0.001
Data are presented as adjusted (geometric) mean values (with 95% confidence interval [CI]). P-values by t-tests for crude mod-
els and by analyses of covariance (ANCOVA) for model 1 and model 2.
Model 1: adjusted for sex, age, body mass index, smoking, and alcohol use at t1; Model 2: additional adjustment for acute-phase 
protein level (hsCRP/albumin) at t1.
a Because of its positively skewed distribution, high sensitivity C-reactive protein was log transformed before the analyses.
b 2 missings for non-users; c 2 missings for non-users, 4 for continuous users; d4 missings for non-users, 4 for continuous users; 
e 4 missings for non-users, 1 for starters and 4 for continuous users.
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It has been shown that plasma levels of cytokines are elevated in Huntington’s Disease (HD) gene 
expansion carriers compared to controls, and are higher in advanced disease stages (1). To test 
the hypothesis that plasma cytokines may serve as a biomarker of disease progression (2), levels 
of pro-inflammatory and anti-inflammatory cytokines were measured in different disease stages 
at baseline and during the 2-year follow-up.
methods
In a cohort of 124 HD gene expansion carriers [described in (3)], of whom 92 could be reassessed 
at 2-year follow-up, plasma levels of tumor necrosis factor a (TNF-a), interleukin (IL)-1b, IL-1 
receptor antagonist (ra), IL-5, IL-6, IL-8, and IL-10 were measured. High sensitivity (hs) ELISA 
assays were used to measure TNF-a, IL-1b, IL-6, and IL-10. Coefficients of variation ranged from 
5.9-64%. The diagnostic confidence level (CL) of the Unified Huntington’s Disease Rating Scale 
(UHDRS) was used to define pre-motor symptomatic (CL 0-1) and motor symptomatic (CL 2-4) 
HD (5). The disease burden score (6), the Total Functional Capacity (TFC) scale (4), and the 
Total Motor Score (TMS) of the UHDRS were used as measures of disease progression. To as-
sess longitudinal changes, paired-sample t-tests were used. Group comparisons were conducted 
using independent sample t-tests. Associations between disease stage and cytokine levels were 
analyzed using data from both assessments by multilevel analysis, accounting for covariance.
results
At baseline, the average age of participants was 49 years, 56% were male and 27% were pre-motor 
symptomatic. During the 2-year follow-up, increases were found in the levels of TNF-α [1.48 pg/
mL standard error (SE) 1.05 pg/mL vs. 1.65 pg/mL SE 1.06 pg/mL, p=0.01] and IL-10 (0.38 pg/
mL SE 1.03 pg/mL vs. 0.41 pg/mL SE 1.03 pg/mL, p=0.04). Motor symptomatic participants had 
higher levels of IL-6 than pre-motor symptomatic participants (0.98 pg/mL SE 1.06 pg/mL vs. 
0.64 pg/mL SE 1.07 pg/mL, p=0.007). Levels of IL-5 were lower in motor symptomatic compared 
with pre-motor symptomatic participants (0.075 pg/mL SE 1.25 pg/mL vs. 0.151 pg/mL SE 1.25 
pg/mL, p<0.001).
With regard to measures of disease progression, only the levels of IL-6 and IL-8 were inversely 
associated with the TFC score, indicating higher levels in more advanced disease stages (Table 1). 
After exclusion of participants who had an inflammatory disease, used anti-inflammatory agents, 
or had hsCRP levels >10 mg/mL (38 time points), effect sizes were not attenuated. No association 
was found between cytokine levels and disease burden score or TMS.
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dIsCussIon
In the present study, in the total group of HD gene expansion carriers, an increase was found 
TNF-α and IL-10 levels during the 2-year follow-up. This may reflect a reactive elevation of anti-
inflammatory cytokines after the initial pro-inflammatory response.  IL-6 and IL-8 were inversely 
associated with the TFC score, whereas no association was found for the other cytokines and 
measures of disease progression. These findings are only partly in agreement with previous re-
ports in which cytokine levels also correlated with estimated time until onset of disease (derived 
from the disease burden score) and with TMS (1). Therefore, currently, we cannot decisively 
conclude that cytokines are useful biomarkers of disease progression in HD. 
A limitation of the present study is that we did not control for diurnal variation of cytokine 
levels. Also, the coefficients of variation were high for IL-1ra, IL-8 and IL-5, thereby increasing 
the probability of a type II error. Future studies should track cytokine levels in larger populations 
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Background: In Huntington’s disease (HD) the innate immune system is activated, as reflected by 
increased plasma levels of different cytokines.  Objective: To explore whether increased cytokine 
levels are associated with neuropsychiatric symptoms and cognitive dysfunction in HD mutation 
carriers. Method: Plasma cytokine levels of TNF-alpha, interleukin (IL)-1ra, IL-1β, IL-5, IL-6, 
IL-8 and Il-10 were assessed in 124 HD mutation carriers at two time points 2 years apart (total-
ling 214 observations). Using multilevel regression analysis, cytokines were analysed in relation 
to neuropsychiatric symptoms and cognitive dysfunction. Depressed mood was assessed with 
the depression subscale of the Problem Behaviours Assessment (PBA), apathy with the Apathy 
Scale, and irritability with the Irritability Scale. Cognitive functioning was assessed using the 
Mini-Mental State Examination (MMSE) and a battery of executive cognitive functioning tests, 
aggregated into an executive cognitive functioning (ExCog) score. Results: Inverse associations 
were found in adjusted models between IL-6 and ExCog score (β =–0.114; p=0.01) and between 
IL-1ra and ExCog score (β=–0.110; p=0.02). No associations between cytokine levels and any of 
the other neuropsychiatric symptom scores remained statistically significant in adjusted models. 
Conclusion: Higher plasma levels of IL-6 and IL-1ra are weakly associated with cognitive dys-
function in HD, but not with other neuropsychiatric symptoms.
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IntroduCtIon
Huntington’s disease (HD) is an autosomal dominant heritable disease, characterized by neu-
ropsychiatric symptoms, cognitive dysfunction and motor disturbances [1]. The prevalence 
of neuropsychiatric symptoms ranged between 33%-69% for a depressed mood, 34%-76% for 
apathy and 33%-73% for irritability [2, 3]. Neuropsychiatric symptoms may occur at any disease 
stage; only the prevalence of apathy is clearly positively associated with progression of the disease 
[4]. Executive cognitive impairment is a prominent component of cognitive dysfunction in HD 
and is positively correlated with disease progression and with whole brain volume loss. Execu-
tive cognitive impairment can become noticeable already an early stage in HD patients [1, 5]. 
HD is caused by an expanded cytosine-adenine-guanine (CAG) repeat in the huntingtin protein 
gene on the short arm of chromosome 4. This genetic defect leads to the expression of mutant 
huntingtin (mhtt). The exact pathophysiological mechanisms by which mhtt causes HD is not yet 
fully understood [6].
The role of immune activation in HD neurodegeneration is supported by several lines of 
evidence [6, 7]. Activated microglia – the immunocompetent cells in the central nervous system 
(CNS) – have been demonstrated in post-mortem samples [8] and on cerebral positron emission 
tomography (PET)-scans [9] of HD patients. Immune activation has also been demonstrated in 
plasma of HD patients and may reflect immune activation within the CNS [10]. Several cross-
sectional studies have shown increased plasma levels of different cytokines in HD, such as 
interleukin [IL]-6, soluble (s) IL-2 receptor (R), s tumor necrosis factor (TNF)-αR, IL-4, IL-5, 
and IL-10. Particularly IL-6 levels were found to be consistently higher in HD mutation carriers 
than in matched controls [10-13]. Levels of IL-6 also correlated positively with the disease stage 
of HD [10]. 
In an earlier investigation, we studied the association between plasma acute-phase protein 
C-reactive protein (CRP) and neuropsychiatric symptoms including cognitive dysfunction. Since 
CRP is synthesized in the liver predominantly under the influence of several pro-inflammatory 
cytokines such as IL-6, the results of that study are relevant to our current investigation. Plasma 
levels of CRP were associated with disease progression, apathy, and cognitive dysfunction[14]. 
However, these results were likely mediated by the use of antipsychotics that may have augmented 
the hepatic production of CRP.
To date, plasma levels of cytokines have not been linked to the occurrence of neuropsychiatric 
symptoms and cognitive dysfunction in HD. In study populations other than HD, levels of plasma 
cytokines have been associated with neuropsychiatric symptoms like anger, hostility, irritability, 
apathy, depression and cognitive dysfunction [15-23]. In line with the findings in other popula-
tions, we expect positive associations between pro-inflammatory cytokines and, more speculative, 
inverse associations between anti-inflammatory cytokines on the one hand and neuropsychiatric 
symptoms and cognitive dysfunction, on the other hand. Since the highest level of plasma cy-
tokines have been found in late disease stages [10], we expect to find the strongest associations 
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between cytokines and apathy and cognitive dysfunction in late disease stages. We investigated 
these associations using all data of up to two time points in HD mutation carriers, taking into 
account the covariance between both measurements that were two years apart from each other.
materIals and methods
Population
In total, 124 HD mutation carriers comprising both pre-motor symptomatic and motor symp-
tomatic mutation carriers were recruited from the outpatient departments of Neurology and 
Clinical Genetics of the Leiden University Medical Center and a regional nursing home special-
ized in care for advanced HD patients. The study design is described in detail elsewhere [24]. All 
participants were proven HD mutation carriers with a CAG repeat length ≥ 36 repeats. Baseline 
measurements were conducted between May 2004 and August 2006. Two years later a second 
measurement was conducted and a third measurement two years thereafter (Figure 1). Blood 
samples suitable for determination of cytokine levels were drawn only at the second and third 
measurement. Thus, for the present study, data from the second and third measurement were 
used, referred to as t1 and t2 hereafter. The study was approved by the medical ethical committee 
of the LUMC and informed consent was obtained from all participants.
152 mutation carriers
Subjects recruited from department of Neurology 
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Specimen collection and storage
EDTA samples were collected and centrifuged for 15 minutes at 3000 g within 30 minutes of 
collection. Blood samples were collected between 9 am and 3 pm, but time of withdrawal was 
not ascertained for each blood sampling. EDTA-plasmas were aliquoted in 500 µL fractions in 
cryo vials from Sarstedt and stored at -80 °C until analysis took place. EDTA-plasmas sampled 
at t1 had median (min-max) storage times of 328 (246-361) weeks before cytokine analysis; t2 
samples were stored up to 170 (77-203) weeks before analysis. Plasma aliquots used for IL1ra, IL5 
and IL8 were thawed twice before analysis, whereas plasma aliquots used for high sensitivity (hs) 
IL-1b, hs IL6, hs IL10, hs TNF-a were thawed only once. Samples were assessed in duplicates, 
taking the average of both measurements. To explore the possibility of IL-6 degradation due to 
prolonged storage in the freezer, we performed an analysis correlating levels of IL-6 with levels of 
C-reactive protein (CRP) which are known to be stable during storage. In this analysis, we found 
a correlation of 0.49 which is comparable to the correlation of 0.49 found in a large meta-analysis 
that comprised 19,053 participants [25]. In our sample of 90 HD patients with assessments at 
both time points, correlation coefficients varied between between 0.483 and 0.728 (P<0.001).
Cytokine Reagents
Cytokine analyses were done using traditional uniplex ELISA’s, the assay in principle being based 
on quantitative sandwich enzyme immunoassay technology. Standardization is done according 
to purified NIBSC/WHO recombinant standards. Analytical selectivity is guaranteed by means 
of pre-coated monoclonal antibodies, specific for each cytokine under investigation. Detection 
took place using a Reader SpectraMAX250 (Molecular Devices) and Softmax Pro calculation 
software (version 5.4). The cytokines IL6, IL10, TNFα and IL1β were measured with Quantikine® 
hs Human Immunoassay kits from R&D Systems. These hs ELISA’s for IL1b, IL6, IL10 and TNFa 
are optimized for measuring cytokines in the low plasma range with inter-assay coefficients of 
variation (CVs) below 10%. Minimum detectable levels, defined as two standard deviations 
above the mean of twenty zero standard replicates, are 0.057; 0.039; 0.09 and 0.106 pg/mL for 
IL1b, IL6, IL10 and TNFa  respectively. The cytokines IL8, IL1-ra and IL5 were analysed with 
Quantikine® ELISA Human Immunoassay from R&D Systems, which is the non-high sensitivity 
version as the high sensitivity version is not available. These ELISA’s are optimized for cytokines 
in the pathophysiological range. Minimum detectable levels are 6.26; 0.29 and 3.5 pg/mL for 
IL1ra, IL5 and IL8.  
Assessment of neuropsychiatric symptoms
Depressive mood was assessed using the depression subscale of the Dutch translation of the 
Problem Behaviours Assessment (NL-PBA) [24]. This scale has a range from 0 to 80. Apathy was 
assessed using the Apathy Scale[26], a 14-item questionnaire with a sum score range between 
0 and 42. Caregivers’ information and the interviewers’ judgment were included in rating the 
Apathy Scale, since patients with apathy may lack adequate insight into their own symptoms. 
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Irritability was assessed using the irritability scale[27], a 14-item questionnaire with a sum score 
range between 0 and 42. 
Assessment of cognition
Global cognitive functioning was assessed using The Mini-Mental State Examination (MMSE) 
[28]. Executive cognitive functioning was assessed using the cognitive scales of the Unified 
Huntington’s Disease Rating Scale (UHDRS), including the Verbal Fluency Test (VFT)[29] the 
Symbol Digit Modalities Test (SDMT)[30], and the three Stroop tests [31]. For all cognitive 
scales, lower scores indicate worse executive functioning. Because of substantial co-linearity 
between the executive cognitive functioning scales (Pearson’s r > 0.80), executive cognitive 
functioning was summarised in the ExCog variable, a composite variable obtained by averaging 
the standardized z-scores of the five executive cognitive scales (i.e. VFT, SDMT and Stroop tests). 
Assessment of clinical characteristics
Information on sociodemographic and clinical characteristics including alcohol consumption, 
use of psychotropic medication and information about the household was collected in a stan-
dardized manner. Global daily functioning was assessed using the Total Functional Capacity 
(TFC) scale of the UHDRS[32]. Trained neurologists assessed motor symptoms using the motor 
section of the UHDRS (UHDRS-m). Mutation carriers with an UHDRS-m confidence level >1 
were considered motor symptomatic. Disease stage was classified according to functional status 
(TFC) in five categories with scores on the TFC of 11 to 13, 7 to 10, 3 to 6, 1 to 2 and 0 cor-
responding to disease stages I, II, III, IV and V, respectively. Stages I – III were defined as early 
disease and stages IV-V as late disease.
Statistical analysis
Data are presented as n (%), mean (± standard deviation [SD]), mean (95% CI), or median 
(inter-quartile range [IQR]), when appropriate. Because of skewed distributions of values and 
residuals in our regression analyses, scores on the irritability scale, apathy scale and PBA depres-
sion subscale were naturally loge-transformed. After loge-transformation, residuals displayed 
approximately normal distributions. For the ExCog score, no such transformation was necessary. 
Multilevel regression models (i.e., Mixed Models) were used to analyse the association between 
cytokine levels (i.e. independent variable) and neuropsychiatric symptoms (i.e. dependent vari-
able) using a two–level structure, with plasma cytokine levels at the two time points as the lower 
level and patients as the upper levels. To increase power, we used data from both time points, 
taking into account the covariance between both measurements within patients. In multivariable 
models, we adjusted for sex, age, body mass index (BMI), smoking and the use of antipsychotics. 
We used a compound symmetry covariance matrix to ensure that data from the same individual 
at two different time-points are not treated as independent observations. We chose not to adjust 
for disease stage as we hypothesized that inflammation (reflected in serum cytokine levels) is 
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part of the causal pathway between disease progression and neuropsychiatric symptoms, and 
therefore adding disease stage as a confounding variable would lead to over-adjustment. To 
ascertain whether the associations between cytokine levels and outcome variables were stronger 
in late versus early disease stages (defined as Stages IV–V vs. I-III according to TFC), appropriate 
interaction terms were added to the statistical models. To adjust for the potential confound-
ing effect of prevalent infections, a sensitivity analysis was carried out in which we excluded 
18 observations with hsCRP levels > 10 mmol/mL. Also, a partial correlation coefficient was 
calculated for the similarity of levels at second measurement and third measurement and for the 
correlation with hsCRP as a measure of validity. The SPSS 21.0 software package was used for 
statistical analyses. A two-tailed p-value <0.05 was considered to denote statistical significance.
results
Population characteristics
Data from 124 observations at t1 and 90 observations from t2 were available and used in the pres-
ent analysis. (Table 1) On average, mutation carriers were 50.7 years old, 57% was male, 71% was 
motor symptomatic and the average TFC score was 7.7. Twenty percent of the mutation carriers 
were in a late stage. Cytokine levels could not be obtained in 5 mutation carriers. In addition, 
data was missing for the apathy scale, irritability scale, MMSE and ExCog in respectively 1, 2, 2 
and 4 mutation carriers out of the 214 observations.
Associations between cytokine levels and neuropsychiatric symptoms
No associations were found between cytokine levels and the PBA depression subscale score, 
neither in univariate nor in multivariate models. The apathy scale score was positively associated 
with Il-1β, IL-6 and IL-8, but after adjustment for sex, age, BMI, smoking status and the use of 
antipsychotics, these associations were no longer statistically significant. No associations were 
found between cytokine levels and irritability. The score on the MMSE was inversely associated 
with IL-1β and IL-1ra, but again only in crude but not in adjusted models.
The ExCog score was inversely associated with IL-6 and IL-1ra in both crude and adjusted 
models (β= -0.114 and β= -0.110, respectively; Table 2 and Figure 2). Interaction terms between 
disease stage and cytokine level for the relationship with ExCog were not statistically significant. 
When excluding a total of 18 observations with hsCRP levels > 10 mmol/mL, effect sizes for the 
adjusted association between ExCog on the one hand and both IL-6 and IL-1ra on the other 
hand remained significant (β= -0.192, p <0.001 and β= -0.125, p=0.02, respectively). Also, after 
adjustment for hsCRP levels, the effect sizes for the adjusted association remained similar and 
significant (β= -0.146, p=0.003 and β= -0.108, p=0.04, respectively).
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table 1 Characteristics of mutation carriers at t1 and t2
t1 t2
    n=124 n=90
Demographic characteristics
Age 49.3 ± 11.7 52.6 ± 11.5
Sex (male) 69 (56%) 53 (59%)
BMI 25.6 ± 5.1 25.9 ± 5.7
Smoking 31 (25%) 25 (28%)
Clinical characteristics
CAG repeats 44.1 ± 3.2 43.9 ± 3.0
UHDRS-m score 30.2 ± 28.6 35.6 ± 31.3
Motor symptomatic n 88 (71%) 63 (70%)
TFC score 7.7 ± 4.9 7.6 ± 4.7
Late stage 26 (21%) 17 (19%)
Use of antipsychotics 28 (23%) 31 (34%)
Neuropsychiatric characteristics
PBA depression score 9.7 ± 14.3 9.9 ± 13.0
Apathy scale score 8.6 ± 8.7 12.1 ±9.3
Irritability scale score 10.2 ± 8.3 11.7 ± 7.5
MMSE score 26.2 ± 4.7 25.3 ± 5.7
ExCog score 0.03 ± 0.94 -0.04 ± 1.08
Data are presented as mean (±standard deviations) or number (percentage) where appropriate. BMI denoted Body Mass In-


































































































































































































































































































































































































































































































































































































































































































































































































We found that higher plasma levels of unstimulated IL-6 and IL-1ra showed a weak association 
with more cognitive executive dysfunction. We found no support for our hypothesis that these 
associations would be stronger in moderate and late stages of HD as compared to early stages. 
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Our findings that levels of IL-6 and IL-1ra in plasma were associated with cognitive 
dysfunction have not yet been reported in HD. In non-HD populations, levels of cytokines in 
relation to cognitive dysfunction have been studied most extensively in patients with Alzheimer’s 
disease (AD), showing that particularly IL-6 and TNF- levels were associated with cognitive 
dysfunction in some, but not all studies among patients with AD [20]. Both IL-6 and IL-1ra 
play an important role in the acute-phase response. Upon disturbance of the homeostasis by 
infection or tissue injury, cells of the innate immune system become activated and release pro-
inflammatory cytokines [33]. One of the major pro-inflammatory cytokines is IL-6 [34]. Il-6 
initiates the acute-phase response by induction of a systemic reaction comprising hepatic release 
of C-reactive protein (CRP) [35], the release of other pro-inflammatory cytokines and, activa-
tion of the hypothalamic-pituitary-adrenal axis [36]. Another effect of IL-6 is the induction of 
IL-1ra [37]. IL-1ra is an inhibitor of the pro-inflammatory cytokine IL-1beta [38]. Thus, IL-1ra is 
regulator of the acute phase response by providing a feedback mechanism for the systemic effects 
of pro-inflammatory cytokines. 
Given the cross-sectional nature of our investigation, the association between the cytokines 
IL-6 and IL-1ra with cognitive dysfunction may be explained by either causal effects, reverse cau-
sation, or confounding by another process. For a causal effect to become likely, IL-6 and IL-1ra 
in the peripheral plasma should be able to influence the CNS in some way. Two direct pathways 
between the peripheral plasma and the CNS exist [39]. First, cytokines can be transported by 
active passage though the blood brain barrier [40]. Second, cytokines can diffuse passively into 
the CNS in the choroid plexus [41]. Furthermore, IL-6 can increase the permeability of the 
blood-brain barrier[42], thereby allowing toxins to enter the brain that can interfere with brain 
functions such as cognition. Indirectly, the CNS can be affected by stimulation of the vagal nerve 
by intra-peritoneal cytokines [43]. Also, under certain conditions, microglia and endothelial 
cells in the brain produce inflammatory factors [43]. Once in the brain, cytokines can activate 
other microglia which in turn secrete their own pro-inflammatory cytokines [44]. This activa-
tion of microglia has indeed been demonstrated by several studies, in both PET scans [9] an in 
post-mortem brain tissue of HD patients [8]. Long-term exposure to cytokines, together with the 
presence of activated microglia may lead to neurodegeneration that causes cognitive dysfunction 
[39, 45]. In earlier studies, it has further been demonstrated that exposure to pro-inflammatory 
cytokines such as IL-6 impairs neurogenesis [39, 46, 47]. Also, due to its atherothrombotic 
potential, IL-6 may induce vascular pathology that contributes to neuronal dysfunction [48]. On 
the other hand, tissue damage due to neurodegeneration in HD caused by other pathophysiologi-
cal mechanisms may be a common cause of both elevated plasma cytokine levels and cognitive 
dysfunction and may thus be a confounder for the relationship we found.
We were not able to demonstrate associations between cytokines and the neuropsychiatric 
symptoms depression, apathy and irritability.  This finding contrasts with previous studies in 
non-HD populations demonstrating associations of cytokine levels with several neuropsychiatric 
symptoms [15-23].  Depressive symptoms in relation to plasma cytokines have been extensively 
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investigated. In a meta-analyses of over 60 studies measuring depressive symptom severity, both 
IL-1 and IL-6 levels were increased in patients with a depressive disorder versus controls (Cohen’s 
d=0.35 and d=0.25, respectively) [49, 50]. Another meta-analysis of 24 studies among patients 
with major depressive disorder (MDD) showed that TNF-α and IL-6 levels were significantly 
higher in 492 patients compared to 400 controls [51]. No significant differences for IL-1β, IL-8, 
and IL-10 levels were found. Moreover, trials in cancer and hepatitis C patients also showed the 
increased risk of depression when treated with interferon (IFN)-gamma [15, 19]. Apathy and loss 
of interest have been studied less often in relation to inflammation; levels of IL-6 have been asso-
ciated with these neuropsychiatric symptoms in 48 stroke patients [50]. The association between 
plasma cytokines and the hostility and anger seen in irritable subjects has been investigated both 
in healthy populations and patient groups [16-18, 21-23]. Observational studies showed that 
IL-1, IL-6, IL-8 and TNF-a were associated with higher levels of anger in populations of healthy 
couples [16], and healthy men [23] and women [22]. Intervention studies in hepatitis C patients 
showed increased anger and hostility upon treatment with IFN-gamma [17, 18]. However, these 
previous studied did not include HD patients, and our contrasting findings may be explained by 
disease specific factors of HD. Neurodegenerative changes in frontal-striatal circuits in HD may 
account for several neuropsychiatric symptoms, thereby obscuring the subtle associations with 
plasma cytokines, that tend to vary considerably over time. 
The strengths of this study are the relatively large cohort of HD mutation carriers assessed at 
two time points, and the use of robust high sensitivity ELISA assays for the assessment of cytokine 
levels. Also some limitations warrant discussion. First, the average storage time of plasma samples 
was 3 years and it has been demonstrated that levels of particularly IL-6 may degrade significantly 
over longer storage times [52]. In addition, we did not ascertain time of withdrawal of our blood 
samples. As a consequence, this may have resulted in a measurement error, resulting in an under-
estimation of the association with cognitive dysfunction. We found however, that cytokine plasma 
levels were rather stable and that measurement error was therefore likely within acceptable limits. 
As a limited number of HD mutation carriers completed both the second and third measurement 
(n=90), we could not perform longitudinal analyses because of the low statistical power as rela-
tively few HD patients had new-onset neuropsychiatric symptoms during the 2 years of follow-up. 
Therefore, given the cross-sectional nature of our study, we cannot infer causal relationships.
In conclusion, levels of IL-6 and IL-1ra were positively associated with executive cognitive 
dysfunction in our cross-sectional study among HD mutation carriers. A causal relation may 
exist between pro-inflammatory cytokines and executive cognitive dysfunction; however the 
association may also be confounded by the neurodegenerative process or by environmental fac-
tors. No associations were found between cytokine levels and other neuropsychiatric symptoms. 
Precise measurement of both cytokine levels as well as of neuropsychiatric symptoms is difficult 
and may introduce errors. Our results should therefore be interpreted with caution. Future stud-
ies should have a longitudinal design to assess possible causal or alternative relations and should 
be designed to further reduce measurement errors.
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general dIsCussIon
In this thesis, we investigated the activity of the innate immune system in HD as reflected in 
several inflammatory immune parameters. Also, we aimed to gain further insight into the 
neuropsychiatric symptoms in HD, in particular irritability. In addition, we investigated the as-
sociation between inflammatory immune parameters on the one hand and measures of disease 
progression (including neuropsychiatric symptoms and cognitive decline) on the other. In aging, 
and in neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease, (neuro)
inflammation is associated with the loss of normal functioning. Investigation of inflammatory 
immune parameters of inflammation in relation to markers of disease progression may provide 
further insight into the development of symptoms of HD. Also, inflammatory immune param-
eters that reflect disease severity in HD may be used as biomarkers in research and clinical care. 
In HD, such biomarkers are important because they may help to detect whether or not a potential 
therapeutic intervention is beneficial [1, 2]. We expected to find a correlation between increased 
levels of pro-inflammatory cytokines and positive acute-phase proteins on the one hand and 
markers of disease progression on the other; we also expected that, with progressing disease, 
levels of regulatory anti-inflammatory cytokines would decrease. Finally, we also expected to find 
an association between levels of immune parameters and neuropsychiatric symptoms.
IntegratIon of the study fIndIngs Into Current knowledge
Irritability
We assessed the psychometric properties of the Irritability Scale (IS) and established that a cut-off 
point of 14 provides a valid and reliable assessment of irritability in HD gene expansion carriers. 
Using the IS, in our HD population the prevalence of irritability in the past two weeks 
was 35%, whereas in other studies the prevalence ranged from 33-73% [3]. These differences in 
reported prevalence can probably be attributed to the wide range of instruments used to assess 
irritability, the different time periods of the studies, as well as the sociodemographic and clinical 
differences in the HD populations investigated. Currently, the IS the only symptom-specific scale 
that is recommended for the assessment of irritability in HD [4]. Although several scales are 
available that assess irritability as one of the behavioral domains (such as the UHDRS behavioral 
subscale), these subscales have either not been extensively validated[5] or no data are available 
on their reliability or other psychometric properties in HD [6-8]. 
In our study, the incidence of irritability was found to be 23% over a two-year period. The 
rate of remittance (for which we were unable to find any predictors) was comparable to the in-
cidence of irritability over time. Increasing irritability was associated with increased apathy and 
the continuous use of antipsychotics. However, we found no correlation between irritability and 
measures of disease progression, such as cognitive decline, motor abnormalities and functional 
Chapter 7
88
incapacity. Also, at baseline, none of these parameters could predict the incidence of irritability 
over a two-year period. Earlier studies showed that irritability may be a characteristic neuro-
psychiatric symptom of pre-manifest and early HD[9-11]. This is in line with findings of more 
recent imaging studies that demonstrated functional changes in the brain of gene expansion 
carriers, specifically for the early stages of HD, that correlated with irritability[12, 13]. Possible 
explanations for the development of irritability include overcompensation of damaged circuits 
early in the disease[13] and cognitive overload caused by early cognitive decline[12]. Also, the 
construct of irritability as assimilated in the IS may lose validity in later stages of HD because of 
the interference of severe motor dysfunction, cognitive decline and neuropsychiatric symptoms. 
Immune parameters 
We found that activation of the acute-phase response, as reflected in levels of both positive and 
negative acute-phase proteins, was associated with impaired daily functioning, apathy and cog-
nitive impairment. However, these associations were confounded by the use of antipsychotics. 
Gene expansion carriers that continuously used antipsychotics had higher levels of hsCRP and 
lower levels of albumin than gene expansion carriers who did not use antipsychotics during the 
study period. In other HD cohorts, CRP levels were significantly increased in advanced disease 
stages when compared to healthy controls; to our knowledge, in these cohorts, no adjustment 
was made for the use of antipsychotics.
Levels of TNF-α and IL-10 increased over the two-year study period. Pre-motor symptom-
atic gene expansion carriers had lower levels of IL-5 and IL-6 than symptomatic gene expansion 
carriers. IL-6 and IL-8 were inversely associated with daily functioning. Also, increased levels of 
both IL-1ra and IL-6 were independently associated with impaired cognitive functioning. Previ-
ous cross-sectional studies with a limited number of mutation carriers in disease stages from 
premanifest to moderately advanced disease stage, presented evidence for increased immune 
activation in the plasma of HD mutation carriers[14-18]. Most consistently, levels of IL-6 were 
higher in motor symptomatic HD mutation carriers than in matched controls, whereas increased 
plasma levels of sIL-2R, sTNF-αR[18], IL-8, and TNF-α [14] were also found. The study that 
assessed IL-4, IL-5, and IL-10, found positive correlations with a more advanced disease stage, 
although levels of IL-4 and IL-5 were increased only in a moderately advanced disease stage, 
compared with controls[14].
The triggering of innate immune activation is also emerging in other neurodegenerative 
diseases[19]. However, the relationship between immune activation and disease progression is 
complex. In Alzheimer’s disease, inflammatory pathways are activated as reflected by increased 
levels of chemokines and cytokines in both the brain and cerebrospinal fluid of patients, and 
neuroinflammation has been demonstrated by PET scans[20]. On the other hand, inflamma-
tory processes are also a risk factor for Alzheimer’s disease. Studies on patients with Alzheimer’s 
disease have demonstrated the negative effects of severe infection[21], sepsis[22] and periodon-
titis[23] on cognition.  
89
General discussion and summary
By chance, we found evidence for activation of the acute-phase response in gene-expansion 
carriers who used antipsychotics. This was found when adjusting for the use of antipsychotics in 
the relationship between acute-phase proteins on the one hand, and daily functioning, cognitive 
impairment and apathy on the other. After this adjustment, effect sizes for these relations were 
considerably reduced and no longer significant. Furthermore, the group of gene-expansion car-
riers that continuously used antipsychotics had higher levels of CRP and lower levels of albumin 
than those who did not use antipsychotics. To our knowledge, this phenomenon has not earlier 
been described. 
Antipsychotics are frequently prescribed in late-stage HD for the symptomatic treatment of 
movement disorder. Therefore, the idea that increased acute-phase response activity is at least 
partly due to the use of antipsychotics is in line with a study reporting that premanifest and 
early-HD gene-expansion carriers had similar lower CRP levels compared to controls[24]. In 
non-HD populations, two pathways for activation of the acute-phase response by antipsychotics 
have been described. First, low-grade inflammation may be the result of obesity[25], dyslip-
idemia[26] and insulin resistance[27] which are elements of the metabolic syndrome, a well-
known side-effect of second-generation antipsychotics. Second, both classical antipsychotics[28] 
and second-generation antipsychotics[29] may directly induce low-grade inflammation through 
their hepatic impact. 
Strengths and limitations
The strengths of this study are the cohort study design and the well-characterized study popu-
lation with HD. Furthermore, we included a control group consisting of first-degree relatives 
without the HD gene expansion which had been exposed to a similar environment as the gene 
expansion carriers. Also, the group of gene-expansion carriers was heterogeneous, comprising 
a range of pre-manifest individuals many years from clinical onset to institutionalized patients 
with end-stage disease. In addition, the same individuals were interviewed up to three times, 
with a two-year interval in between. Specifically, we used valid and reliable measurement tools in 
a standardized setting. Dropout rates between measurements were moderate and did not exceed 
20%. Cytokine levels were also measured in a standardized and state-of-the-art manner. Where 
possible, we used high-sensitivity enzyme-linked-immuno-sorbent assays (ELISA); due to their 
conceptual design, ELISAs are less prone to altered levels of circulating proteins and inhibitors 
than multiplexed immunoassays[30]. Also, the number of freeze-thaw cycles was limited to one 
(for IL1-b, IL-6, IL-10 and TNF-α) or two (for IL-1ra, IL-5 and IL-8). Third, the methodological 
design eliminated any plate-to-plate and/or lot-to-lot variation and/or operator variability, as 
paired samples from HD gene expansion carriers were measured simultaneously on the same 
plate for the longitudinal analyses. Fourth, significant partial correlations were found for all 
cytokines between paired HD samples, ranging from 0.483 to 0.728 (p<0.001).
Some limitations also need to be addressed. An important drawback is the limited validity 
of the measurement of behavioral symptoms in HD. Validated systems, such as the Diagnostic 
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and Statistical Manual of Mental Disorders (DSM), are used for the classification of psychiatric 
disorders. However, their usefulness in HD is limited because they were not designed to assess 
symptoms and do not assess the severity of symptoms in dimensional scales. Next, cytokine 
levels in the plasma may not accurately reflect the highly complex state of the immune system. 
Although blood and its subsequent handling was done carefully, we were not able to take into ac-
count the effect of diurnal and seasonal changes in cytokine levels, which can be significant[31]. 
Another drawback is that we could not adjust for all possible confounding variables. Medication 
is frequently prescribed for movement disorder and behavioral symptoms; these medications 
include antipsychotics and benzodiazepines, which are known to have a wide range of biological 
adverse effects. Given the observational nature of our study, we could not determine whether 
the associations found were explained by causative mechanisms, confounding, or confounding 
by indication. Given the low incidence of HD, collecting a sufficiently large sample of HD gene 
expansion carriers remains a challenge. In particular, for analyses within subgroups with a siz-
able number of covariates, sample sizes were too low to reach adequate statistical power; because 
this may have caused type-I and type-II errors, our findings need to be replicated in independent 
samples of HD gene-expansion carriers.
Implications for clinical practice
No specific treatment for irritability in HD is available. Current treatment guidelines are largely 
based on case series and expert opinion, and on findings from studies in patients with psychiatric 
or other neurodegenerative disorders[32-34]. Our study showed that, in a significant number of 
patients, irritability may remit over a two-year study period; however, we were unable to predict 
which patients had the highest chance to remit from irritability. Nonetheless, we found that the 
use of benzodiazepines and antipsychotics was associated with the prevalence and incidence of 
irritability, respectively. Both types of drugs can be used in the treatment of irritability; however, 
especially in patients who receive these drugs for other indications, clinicians should be aware 
that irritability might be a possible side-effect. 
Although evidence for increased levels of (low-grade) systemic inflammation was found in 
our population, the cause of this systemic inflammation could not be identified; the inflamma-
tory state most likely reflects a complex system of mechanisms. In other populations, the effects 
of systemic inflammation on mood[35-37] and cognition[38-40] are detrimental. Studies have 
also indicated negative effects on metabolic disease and cardiovascular health[41-43]. Several 
studies have investigated the positive effects of anti-inflammatory drugs in HD. However, until 
now, agents like minocycline[44, 45], cannabinoids[46, 47] and non-steroidal anti-inflammatory 
drugs[48, 49] have not proven effective in humans, although some studies may have been under-
powered. Further studies are needed to assess whether a more specific tweaking of neuroinflam-
mation may benefit the many ailments of HD gene expansion carriers. In HD, treatable causes 
of systemic inflammation, such as infectious processes, should be managed properly. Also, iat-
rogenic damage, caused by the possible adverse effects of prescribed drugs, should be prevented.
91
General discussion and summary
Although our findings offer additional insight into the role of the innate immune system in 
HD, they also indicate that the rather crude immune parameters that we investigated were not 
of clinical use as biomarkers for the individual HD gene expansion carrier. It is important that a 
biomarker is measurable in a cost-effective manner, changes with the disease state over time, and 
is able to discriminate between gene expansion carriers in different disease states. 
Directions for future research
The studies in this thesis confirm that inflammatory processes play an important role in HD. 
Immune parameters, indicating activation of the innate immune system, correlated with neuro-
psychiatric and motor symptoms, as well as with functional decline. However, given the observa-
tional nature of our investigation, we cannot infer any causal relations. Most likely, the immune 
system plays both a pathogenic and homeostatic role; however, more longitudinal studies are 
required to unravel its precise function in HD. Importantly, our findings also demonstrated that 
iatrogenic factors, such as the use of (psychotropic) medication, were related to both immune 
system parameters and outcome measures and, thus, need to be taken into account. 
Although we have provided a thorough assessment of the psychometric properties of the IS, 
these findings still need to be replicated in larger studies. The validity and comparability of the 
scale, and its sum score in different stages of the disease, should be studied further using more so-
phisticated analysis techniques that include confirmatory factor analysis to assess measurement 
invariance. This might help establish whether factor loadings, intercepts and residual variances 
are equivalent in a factor model that measures a latent variable irritability. If so, comparisons of 
irritability scores will be valid across disease stages and across time within a HD gene expansion 
carrier. 
Our findings concerning the associations between immune system parameters on the one 
hand and neuropsychiatric symptoms and disease progression on the other, yielded far more 
modest effect sizes than other studies of a comparable size Therefore, larger studies are needed 
to replicate these findings. Moreover, these studies should be able to adequately assess cytokine 
levels, taking into account possible confounding factors such as diurnal and seasonal variations 
in the levels of cytokines and the use of medication. 
In observational studies, no firm conclusions regarding causality can be drawn. In our 
study, the confounding effect of the use of antipsychotics on immune system parameters and 
neuropsychiatric symptoms, warrants investigating whether this is explained by confounding by 
indication or by a direct effect of these drugs. Therefore, the results of previous studies on anti-
psychotics cannot be generalized. The effectiveness of antipsychotics should be assessed critically 
in well-designed and sufficiently powered studies and be weighed against the possible negative 
consequences, preferably in randomized controlled trials (RCTs) in a HD population. In addition 
to evaluation of the safety of antipsychotics, RCTs can shed more light on the treatment of vari-




In a cohort of HD gene expansion carriers, we assessed neuropsychiatric symptoms and several 
inflammatory immune system parameters. The aim was to investigate neuropsychiatric symp-
toms, in particular irritability, in more detail and gain further insight into the activation of the 
innate immune system in HD, as well as its role in disease progression. 
The irritability scale (IS) was used to assess irritability. This scale proved to be a reliable 
and valid instrument for the assessment of irritability in HD. Using a cut-off point of 14, the 
prevalence of irritability was 35% in our population of HD gene expansion carriers. Gene ex-
pansion carriers tended to underestimate their level of irritability when compared to reports of 
their caregivers or spouses. Being married/living together and a longer CAG expansion in the 
Htt-gene were independent correlates of self-reported irritability. The incidence of new-onset ir-
ritability over a two-year study period was 23% and coincided with an increase of apathy; during 
this period, irritability remitted in 30% of previously irritable gene expansion carriers.
Levels of the pro-inflammatory cytokines TNF-α and IL-10 increased over the two-year 
study period. Also, pre-motor symptomatic gene expansion carriers had lower levels of IL-5 and 
IL-6 than motor symptomatic gene expansion carriers. Additionally, levels of IL-6 and IL-8 were 
inversely associated with the level of daily functioning. 
Activation of the acute-phase response, as reflected by higher levels of CRP and lower levels 
of albumin, was associated with impaired daily functioning, apathy and cognitive impairment. 
However, these associations were confounded by the use of antipsychotics.
A weak association was found between increased levels of both IL-1ra and IL-6 on the one 
hand and cognitive decline on the other. No associations were found between cytokine levels and 
apathy, irritability and depressive mood.
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In dit proefschrift worden neuropsychiatrische symptomen bij de ziekte van Huntington (ZvH) 
beschreven. In het bijzonder wordt stilgestaan bij het vóórkomen en het beloop van prikkel-
baarheid. Tevens wordt de rol van het immuunsysteem onderzocht. Hierbij wordt nagegaan of 
er toegenomen activiteit van met name het pro-inflammatoire gedeelte van het niet-adaptieve 
immuunsysteem optreedt en of deze activiteit van invloed is op het optreden van neuropsychia-
trische symptomen.
Prikkelbaarheid is een tot nu toe niet-gevalideerd construct bij de ziekte van Huntington. 
In hoofdstuk 2 worden de psychometrische eigenschappen van de prikkelbaarheidsschaal (PS) 
beschreven en wordt aangetoond dat de PS een betrouwbaar en valide meetinstrument is voor 
het vaststellen van prikkelbaar. Een afkapwaarde van 14 punten op deze schaal blijkt hiervoor het 
meest betrouwbaar. Gebruik makend van die afkapwaarde wordt de prevalentie van irritabiliteit 
in ons cohort geschat op 35%. Genexpansiedragers onderschatten de mate van hun eigen prikkel-
baarheid als deze wordt vergeleken met de rapportage van zorgverleners of partners. Getrouwd 
zijn en samenwonen, alsmede drager zijn van een langere genexpansie, zijn onafhankelijke cor-
relaten van toegenomen prikkelbaarheid. In hoofdstuk 3 wordt vastgesteld dat de incidentie van 
prikkelbaarheid gedurende 2 jaar 23% is en samengaat met een toename van apathie. In diezelfde 
periode is er sprake van een remissie van 30% van bij baseline vastgestelde prikkelbaarheid.
In hoofdstuk 4 wordt de relatie onderzocht tussen de acuut-fase eiwitten C-reactief proteine 
(CRP) en albumine enerzijds, en het voorkomen van neuropsychiatrische symptomen anderzijds. 
Activatie van de acuut-fase respons blijkt geassocieerd met verminderd algemeen functioneren, 
toegenomen apathie en meer cognitieve achteruitgang. Ook blijkt dat het gebruik van antipsy-
chotica dit verband geheel verklaart en dit gebruik dus mogelijk een oorzaak van beide is.
In hoofdstuk 5 worden de spiegels van zowel pro-inflammatoire als anti-inflammatoire 
cytokinen onderzocht in niet-motor symptomatische genexpansiedragers vergeleken met 
symptomatische genexpansiedragers. De hoogte van deze spiegels wordt gemeten op baseline, 
en bij follow-up 2 jaar later. Daarbij blijkt dat de cytokinen TNF-α en IL-10 gedurende deze 
periode toenemen. Niet-motor symptomatische genexpansiedragers hebben lagere spiegels van 
IL-5 en IL-6 dan symptomatische genexpansiedragers. Ook zijn hogere spiegels van IL-6 en IL-8 
geassocieerd met verminderd algemeen functioneren. Hogere spiegels van IL-1ra en IL-6 zijn 
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